var title_f23_52_24384="Ulcerated hemangioma axilla";
var content_f23_52_24384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcerated hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulceration is the most common complication of hemangiomas. Large tumors, as the one of the axilla depicted above, have increased risk of ulceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24384=[""].join("\n");
var outline_f23_52_24384=null;
var title_f23_52_24385="Upper cervical vertebrae";
var content_f23_52_24385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Anatomy of upper cervical vertebrae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24385=[""].join("\n");
var outline_f23_52_24385=null;
var title_f23_52_24386="Focal dermal hypoplasia";
var content_f23_52_24386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal dermal hypoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous areas representing dermal hypoplasia are present. Note the digital abnormalities involving the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24386=[""].join("\n");
var outline_f23_52_24386=null;
var title_f23_52_24387="Chagas heart disease PA";
var content_f23_52_24387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic Chagas' heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray in a patient with chronic Chagas' heart disease and NYHA class III heart failure shows marked cardiomegaly with virtually no signs of pulmonary congestion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24387=[""].join("\n");
var outline_f23_52_24387=null;
var title_f23_52_24388="Stone fragmentation in vitro";
var content_f23_52_24388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A cholesterol gallstone before and after in-vitro laser lithotripsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lingenfelser TH, Dette S, Scheurlen M, Grund KE. Lithotripsy with the Flashlamp Exited Dye Laser: In vitro effects on gallstones. Lasermedizin 1992; 8:4. Copyright &copy; 1992 Urban &amp;Fischer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24388=[""].join("\n");
var outline_f23_52_24388=null;
var title_f23_52_24389="Tetanus toxoid (adsorbed): Pediatric drug information";
var content_f23_52_24389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetanus toxoid (adsorbed): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3430?source=see_link\">",
"    see \"Tetanus toxoid (adsorbed): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/5/12371?source=see_link\">",
"    see \"Tetanus toxoid (adsorbed): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3430?source=see_link\">",
"      see \"Tetanus toxoid (adsorbed): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     Not indicated for this use; combined antigen vaccines are recommended.",
"     <b>",
"      Note:",
"     </b>",
"     In most patients, Td is the recommended product for primary immunization, booster doses, and tetanus immunization in wound management (refer to diphtheria and tetanus toxoid monograph):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Booster doses:",
"     </b>",
"     Children &ge;7 years, Adolescents, and Adults: I.M: 0.5 mL every 10 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tetanus prophylaxis in wound management:",
"     </b>",
"     Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated, the immunization status of the patient, proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Tetanus Prophylaxis Wound Management",
"     </caption>",
"     <col align=\"center\" width=\"250\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         History of Tetanus Immunization (Doses)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Clean, Minor Wounds",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         All Other Wounds",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Tetanus toxoid in this chart refers to a tetanus toxoid containing vaccine. For children &lt;7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years of age and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Yes, if &ge;10 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Yes, if &ge; 5 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Abbreviations:",
"         <b>",
"          DT",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years);",
"         <b>",
"          DTaP",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel&reg;, Infanrix&reg;);",
"         <b>",
"          Td",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Decavac&reg;, Tenivac&trade;);",
"         <b>",
"          TT",
"         </b>",
"         = Tetanus toxoid (adsorbed [formulation for age &ge;7 years]);",
"         <b>",
"          Tdap",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel&reg; or Boostrix&reg; [formulations for age &ge;7 years]);",
"         <b>",
"          TIG",
"         </b>",
"         = Tetanus Immune Globulin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from the Yellow Book 2010, Chapter 2,",
"         <i>",
"          Routine Vaccine-Preventable Diseases, Tetanus",
"         </i>",
"         ; Available at www.cdc.gov/yellowbook;  and",
"         <i>",
"          MMWR",
"         </i>",
"         , 2006, 55:RR-17.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Uncertain or &lt;3 doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         3 or more doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension: 5 Lf units/0.5 mL (0.5 mL) [contains aluminum and thimerosal (may have trace amounts]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Shake well prior to use. Administer into lateral aspect of midthigh or deltoid muscle of upper arm; may be administered SubQ if intramuscular route cannot be used;",
"     <b>",
"      not for I.V. administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F). Do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indicated as booster dose in the active immunization against tetanus when combined antigen preparations are not indicated (FDA approved in ages &ge;7 years and adults).",
"     <b>",
"      Note:",
"     </b>",
"     Tetanus and diphtheria toxoids for adult use (Td) is the preferred immunizing agent for most adults and for children after their seventh birthday. Young children should receive trivalent DTaP (diphtheria and tetanus toxoids, and acellular pertussis vaccine) as part of their childhood immunization program, unless pertussis is contraindicated, then DT is warranted.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tetanus toxoid products may be confused with influenza virus vaccine and tuberculin products. Medication errors have occurred when tetanus toxoid products have been inadvertently administered instead of tuberculin skin tests (PPD) and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F226121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Brachial neuritis, fever, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Edema, induration (with or without tenderness), rash, redness, urticaria, warmth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular: Arthralgia, Guillain-Barr&eacute; syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, Arthus-type hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetanus toxoid",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered; immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with a history of severe local reaction (Arthus-type) or temperature of &gt;39.4&deg;C (103&deg;F) following a previous dose should not be given further routine or emergency doses of tetanus toxoid more frequently than every 10 years. Guillain-Barr&eacute; syndrome occurring within 6 weeks of tetanus toxoid vaccination has been reported. Defer administration during moderate or severe illness (with or without fever). Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Products may contain thimerosal; vial stopper may contain natural latex rubber.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F744551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Animal studies have not been conducted. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (CDC, 2011). The ACIP recommends vaccination in previously unvaccinated women or in women with an incomplete vaccination series, whose child may be born in unhygienic conditions. Tetanus immune globulin and a tetanus toxoid-containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant women. Vaccination using Td is preferred.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13929318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetanus toxoid preparations contain the toxin produced by virulent tetanus bacilli (detoxified growth products of",
"     <i>",
"      Clostridium tetani",
"     </i>",
"     ). The toxin has been modified by treatment with formaldehyde so that is has lost toxicity but still retains ability to act as antigen and produce active immunity.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13921878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: Primary immunization: ~10 years",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/5/12371?source=see_link\">",
"      see \"Tetanus toxoid (adsorbed): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May experience mild fever or soreness, swelling, and redness/knot at the injection site usually lasting 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10285526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24389/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-4):1-51; published erratum appears in",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(26):723.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24389/abstract-text/18509304/pubmed\" id=\"18509304\" target=\"_blank\">",
"        18509304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24389/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24389/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24389/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24389/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12952 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24389=[""].join("\n");
var outline_f23_52_24389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062494\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062487\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226097\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226084\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062498\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062490\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062497\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226122\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226121\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062500\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062486\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062485\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300120\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226092\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226094\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744551\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929318\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062484\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13921878\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062492\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10285526\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12952\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12952|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3430?source=related_link\">",
"      Tetanus toxoid (adsorbed): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/5/12371?source=related_link\">",
"      Tetanus toxoid (adsorbed): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_52_24390="Chlorpheniramine: Drug information";
var content_f23_52_24390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/16/37124?source=see_link\">",
"    see \"Chlorpheniramine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25413?source=see_link\">",
"    see \"Chlorpheniramine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aller-chlor&reg; [OTC];",
"     </li>",
"     <li>",
"      Allergy Relief [OTC];",
"     </li>",
"     <li>",
"      Chlor Hist [OTC];",
"     </li>",
"     <li>",
"      Chlor-Trimeton&reg; Allergy [OTC];",
"     </li>",
"     <li>",
"      Chlorphen [OTC];",
"     </li>",
"     <li>",
"      Chlorphen-12&trade; [OTC];",
"     </li>",
"     <li>",
"      ED Chlorped Jr [OTC];",
"     </li>",
"     <li>",
"      Ed ChlorPed [OTC];",
"     </li>",
"     <li>",
"      Ed-Chlortan [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chlor-Tripolon&reg;;",
"     </li>",
"     <li>",
"      Novo-Pheniram",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Allergic symptoms, allergic rhinitis:",
"     </b>",
"     Oral:",
"     <b>",
"      Chlorpheniramine maleate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release: 4 mg every 4-6 hours; do not exceed 24 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: 12 mg every 12 hours; do not exceed 24 mg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25413?source=see_link\">",
"      see \"Chlorpheniramine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Allergic symptoms, allergic rhinitis:",
"     </b>",
"     Oral:",
"     <b>",
"      Chlorpheniramine maleate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-5 years: 1 mg every 4-6 hours; do not exceed 6 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years: 2 mg every 4-6 hours; do not exceed 12 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as maleate [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed ChlorPed: 2 mg/mL (60 mL) [contains propylene glycol, sodium benzoate; cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as maleate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aller-chlor&reg;: 2 mg/5 mL (118 mL) [contains ethanol 5%, menthol, propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ED Chlorped Jr: 2 mg/5 mL (473 mL) [ethanol free, sugar free; contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aller-chlor&reg;: 4 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allergy Relief: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlor Hist: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlor-Trimeton&reg; Allergy: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorphen: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed-Chlortan: 4 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as maleate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorphen-12&trade;: 12 mg [contains calcium 28 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food or water. Timed release oral forms are to be swallowed whole, not crushed or chewed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Chlor-Trimeton&reg; may be confused with Chloromycetin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Slight to moderate drowsiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Thickening of bronchial secretions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, excitability, fatigue, nervousness, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, xerostomia, diarrhea, abdominal pain, appetite increase, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpheniramine maleate or any component of the formulation; narrow-angle glaucoma; bladder neck obstruction; symptomatic prostate hypertrophy; during acute asthmatic attacks; stenosing peptic ulcer; pyloroduodenal obstruction. Avoid use in premature and term newborns due to possible association with SIDS.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F149978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal chlorpheniramine use has generally not resulted in an increased risk of birth defects. Antihistamines are recommended for the treatment of rhinitis, urticaria, and pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14389418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information specific to the use of chlorpheniramine is limited. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F149974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or water. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Ed ChlorPed Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (60 mL): $21.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Ed ChlorPed Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (60 mL): $21.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Chlor-Trimeton Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/5 mL (120 mL): $4.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Chlor-Trimeton Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (10): $4.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Chlorpheniramine Maleate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (24): $15.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ahist Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (100): $110.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chlor-Trimeton Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (24): $4.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chlorpheniramine Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $2.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ed-Chlor-Tan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $60.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ahiston (IL);",
"     </li>",
"     <li>",
"      Alerfin (PY);",
"     </li>",
"     <li>",
"      Alergidryl (AR);",
"     </li>",
"     <li>",
"      Alergitrat (AR);",
"     </li>",
"     <li>",
"      Aller (MY);",
"     </li>",
"     <li>",
"      Allerfin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Allergex (ZA);",
"     </li>",
"     <li>",
"      Allergyl (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Allermin (SG, TW);",
"     </li>",
"     <li>",
"      Analerg (UY);",
"     </li>",
"     <li>",
"      Antadex-H (MX);",
"     </li>",
"     <li>",
"      Antamin (MY, PH, SG);",
"     </li>",
"     <li>",
"      Bregamin (MX);",
"     </li>",
"     <li>",
"      Cadistin (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Chloramine (MY, SG);",
"     </li>",
"     <li>",
"      Chlorpheniramine DHA (HK);",
"     </li>",
"     <li>",
"      Chlorpheno (TH);",
"     </li>",
"     <li>",
"      Chlorphenon (ID);",
"     </li>",
"     <li>",
"      Chlorpyrimine (HK, MY, TH);",
"     </li>",
"     <li>",
"      Chlortrimeton (ZA);",
"     </li>",
"     <li>",
"      Clorfam (CO);",
"     </li>",
"     <li>",
"      Cloro Trimeton (AR);",
"     </li>",
"     <li>",
"      Cloro-Trimeton (MX);",
"     </li>",
"     <li>",
"      Cloroalergan (PE);",
"     </li>",
"     <li>",
"      Clorotrimeton (PE, VE);",
"     </li>",
"     <li>",
"      Co-Timine (TW);",
"     </li>",
"     <li>",
"      Cohistan (ID);",
"     </li>",
"     <li>",
"      Com-Trimeton (TW);",
"     </li>",
"     <li>",
"      Derimeton (MX);",
"     </li>",
"     <li>",
"      Histafen (NZ);",
"     </li>",
"     <li>",
"      Histal (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Histat (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Histatapp (TH);",
"     </li>",
"     <li>",
"      Histavil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Histin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Istamex (GR);",
"     </li>",
"     <li>",
"      Niramine (TW);",
"     </li>",
"     <li>",
"      Orphen (ID);",
"     </li>",
"     <li>",
"      Pirafene (BG);",
"     </li>",
"     <li>",
"      Piriton (AE, BB, BH, BM, BS, BZ, CY, EG, GB, GY, IE, IQ, IR, JM, JO, KW, LB, LY, NL, OM, PK, PR, QA, SA, SG, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Trimeton (IT);",
"     </li>",
"     <li>",
"      Valemine (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 4-7 L/kg; Adults: 6-12 L/kg (Paton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 33% (range: 29% to 37%) (Mart&iacute;nez-G&oacute;mez, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP450 enzymes (including CYP2D6 and other unidentified enzymes) to active and inactive metabolites; significant first-pass effect (Sharma, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Serum: Children: 10-13 hours; Adults: 14-24 hours (Paton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 2-3 hours (Sharma, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (Sharma, 2003)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24390/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mart&iacute;nez-G&oacute;mez MA, Villanueva-Cama&ntilde;as RM, Sagrado S, et al, \"Evaluation of Enantioselective Binding of Antihistamines to Human Serum Albumin by ACE,\"",
"      <i>",
"       Electrophoresis",
"      </i>",
"      , 2007, 28(15):2635-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24390/abstract-text/17605150/pubmed\" id=\"17605150\" target=\"_blank\">",
"        17605150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paton DM and Webster DR, \"Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines),\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 10(6):477-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24390/abstract-text/2866055/pubmed\" id=\"2866055\" target=\"_blank\">",
"        2866055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma A and Hamelin BA, \"Classic Histamine H1 Receptor Antagonists: A Critical Review of Their Metabolic and Pharmacokinetic Fate from a Bird's Eye View,\"",
"      <i>",
"       Curr Drug Metab",
"      </i>",
"      , 2003, 4(2):105-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/52/24390/abstract-text/12678691/pubmed\" id=\"12678691\" target=\"_blank\">",
"        12678691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8860 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24390=[""].join("\n");
var outline_f23_52_24390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149979\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149980\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149994\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149983\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149990\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149966\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149953\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149969\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149968\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149998\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149992\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149972\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149957\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149991\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149961\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149978\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630927\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14389418\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149974\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323060\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149975\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149956\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149971\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/16/37124?source=related_link\">",
"      Chlorpheniramine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25413?source=related_link\">",
"      Chlorpheniramine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_52_24391="Rosacea erythema";
var content_f23_52_24391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77020%7EDERM%2F56083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77020%7EDERM%2F56083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDpbq7QHYAXP+zVi1chgURgT2NVraJYVy3Oe9SvconV8Ma8y1ndnrLsiee5kYbVOD7VSjtC75kJb1zViE7jkA/j1NXFZFHzLtI5pOHNqyr8uxXe1VIssBgDpWZtVpctkegFaM0jOW3AbT0xVNIpBIxIGWPT0ptJWsClfclUhFwV59qliVmkUbcA96fbxnGSOasIjPJjHHahxY1JEy25ZeDjsKmjthGgXeSfep4UKKBu6e1TiLzCMnp1rblv6i5iGG3kyTu46kkVZitZGyxbj3FW4Y1GMk89M9B+FWYVVm5I3D1reNInmKS2O8BnY4PGBTxYp0Yu30JxWtHGNozhV9D3od4o9qAl3PUAVt7GC3J52Z6WURGRCp7c859qebMYPyqABzgcitIHCszcY68DA+lVbi5yQkanJ6s3pVuMEgTkyh9iXuRg889cVSNqpbPlE7j8rAcEVrkTyKBhTuwKcbYFMscAfKPQUvZp7I0U2tzBe0BViWLqq44HIqb7IQFMIwMZIxgmr72+yPbFvck4O7ioZWYIu5j5YBG3FS6aS1HzsQbI0BLlpBwar3F5heCAFHXFVZ7sByNxLnj8KwdW1E7THEAOxPrUTrqK0J5G2V9Z1A3E7IrfIOuKw55OuOAO9SOMDJPJOTUFwoPTO2vMlJybbOmMUiK3jEsy7z8pOK3LZCqkccHgms20C7lXHvn2rYhCtFs/SnBW1NkTW4L8Z5HOSKdKFxtcEgd6bkhWAyRjrUMZ+dQzHnjmtGlY6IRvqWlnZ8RouAOhpt3cAxAMMMOMj1prSbe3y9iKpkO0xbdlAR271DKUVuW412kHoAKZKQQ2Pv4yDTJ7n5uMYqtEWLO7PlSelPmvoiJRe5S1Bedw7ckVnIwBYgYFaeoL+7cgE85rMRSCOmG5qdUznktC5bSmILKCR6102n6gdiFj8p9O1ctEc5DD2wKvaXN5b7W59M+lVCTi7nPJdDtAwnQlsMT0yOKtojoiuSGXODxzisi2lG0AMB+NaUMjFQSQDnHJ4NejCcXuZu6RYWPPCx/Nk4PpRCsaxksSWD/KMcH1p8bsWOxC544zU6wJOJNpOd2enSrUb6oXNYngSN5GU43fwkVditlGcAdPxrO8sxnd5hZc9OODT2meOVGdww7FeCKvmt0IeuzLE9mjfOnTqR3qvLaqMgcA9c1IbwY3I4fJ+6eDQ0+9RuLAnuRipbhIVpIz3tyFJyDg8ZqB4VJJ2Vek3ksFKyD17mqrnYTuBU+hrnlFdCtSjIRjaAODzgVUdkYnAxj2rTwueWGTVS7terKfyrGSlbQq66mZNCCwdQR2qHyyd386sIzgtuIZPpTBtbHUYPrWKs+hTM28iUqVcZU9TUtiFj2pwV6c1IzBpCigbvfpULI0TcA464NJK7uiH2Zpi3UHKDmmMoLYHD+lLaTgqoDZ9c9qfcscZwMjvV8i6DVzNVhg7mGFH4VGArN5jAbunTj61CG42hTz0GeTUyOVZQ5+Y8cjpUuwkmXosgqFPJ5zUhJkxt5PQ1DAny72IVemT1qyso2fuxjHc96uO2oNDorctlmXOBgcUOgUjb17n1piSlgQzHA6jNW0K9QRzwPaq5UxWsMTBUA5IHJxxViBs4CLwTxmiIJGcyNvB5wO1Wgwz8i7VzwT2qlC27GK0EzqqhQue5NXbazYRjc3PvTIkZsM5LAf3a0II28vOz8XPFb06Eb81iXJ2IIoiXOXBKnHFXFiwokAZgOeBSRMyykCJSD39KnDTngBh7AZ4/pW8IpIltsdbZkUfugGPTJ5NLLEADlsEcfL1NNijTGd25+5J6VZUxRAFBG0x4y3QVql7vvEt66EUMEYjxJHx2Ut09zSyRxBShC9cswH6VDJOqZdjgnuo4qtPc5AERY+rbalyikNJ3LXmKF3jarAYAPGBUDXaNjYSyJydg4JqlcT7ACmZJj1ZhkfSqPmMw+d/l9B0rKVfWyLUb6l29uvtBOzPyjrnvVC6OUHznIHOTUZuuSoKjHWqF9cbmIVgfpXPOrc0jB3Kl7dqpZlYZrGdGdizZweatyKZHJbAUelVpQc8bsdK45NG6iUZz8zADr7VCQzt0+UVYbG7B/GlCkA4HNZ2LvYWHk8YGO9WllCt1xnp71UyEjCnA/qajjfuORnv0pt9DanG+5uoVMO0kgnnNNeHY4ckYH8OetUIZXY4GSO5qZpHwX+XHoe1VfQ3jBomct5e7AUGorfDKXJYc9qV5MxAlg3qoqIMU4GfxpX1NLaWIbmIm4ZozjI5zUEYaL5iCNxxgn9avSSx4Z3GWIAHtVS7kV4x2NDsTKWlhkkwIxk4JxVaQAY470ZCllOeeaEUuo5AP8AP60XOSSsxrKUl6HnvViM855XHQ0jINw2nd6mhhkfMen3cdqDFq5t2UglbbIePat20YKqqGJ9DXH2U7ROC4wRxXR2Lq4QlgAx7GtqctSZw0ubaOyyAxsEbH51ZhlkWT52bbjqvWqDKqEFH49DTTIUIyGw1dXPYx5bmrI4lCH93/dJPX86dL5i4hRUbvgMDmqsa70AD9up7VLGSU3g7pE/vVfPb5mew623SBvtEQPPBTgmp/3ajKGRR3V+RTWljikVyNvGePWlZ1LCRC20/eycj8KqNthN9SOWPdL/AKsbfVDUE0TbuGEhB7mrziJiCoIJ7joaheNd5YtknrmnKFwUihJIuMPEN3sahaOMqTudferhhVSApz6+4qJj5ZOAeeoPSsuTuO6M1ofvMrhx0xWdcRyRhjD8yj7wPUCte9hVgGjXYTycHiqc6lV3FgX7471hUplozgTtVmUfNzQr/MUY4Ujr6VLIRIMdPpUA2EsGGeKyQWuNiCLIyM2znj0NXlYFNoOT9azpuFA6rn71RSymFQyD5e9PnUdGNRY20TOXbCHGPwqVhtAmyAhOAT3p20s+AcKOvPWobh/MkCgqEA7f0pqOljWEblkzIuNxPThRTJppJYsbwqj0/lVds7N275fcUqNt2jYRkd+lEkzZU1uXIZCkZQsQSOM1LHMdpUPuIOKp7GkKBMDHUkc1IJMuVAyaa0RXs7mnA+8YI5A7VfjnUgEHgevasqz3ldoHrlqlhjChgXOPc96p36GU6aNi21I7ii5Yg9e1XkvNxyxLE9BmuZkYQptUnBPLD1q3ZMVU+Y4P+NTCpNS5WZumrXOhhum3NySW4OBipxeMj45JA4Ocfn61zkl2xfAbGO3Y0outqlmIGOuK6I1mtER7K+pvm+MQCo4BzztGQKqTTmY5IGCOWJ/Wspb+OQDD7gOvvUb3Y+YEg57DpWUqt+o40n2NNZyXzuzjoQaf9qk+6QQOvB+9WXFdxxnbuG2hp2YnypOPU0KemjK9k2X7mdQMsQMVnSXO4HaRioSXmyOevWojFjhTk98VEptm0KSS1GhWd225pXiRUXcME9atRIqIWIOe3rUd5EdoLn5h0ArKWiG9XYy5iNvGQB0FVZyAmMCrVyro3XH4VQcE5BP1rIaiUnf94Cp4znNTKSc5PHWmlSCODinFxFyRniiOxMmRSbXAZ+Oy1EJVKCOP5c9W9aHl8xgox/hU6wJEQQOT3Panc6KegLJIoC84z1qwWDqBuyM8gVGsBd8+ZkY6AVJGpO5d3IHAFQdJJtyp2jHHWl2F485yRwM96g3yoCqAAHjimC58vhgFX3prQGnbQLpmAOFAIqjLKDEN/BpJJyZiFJwaZK4OdzfiKGxND4sMqnJJHrUpRhJkHg/pVESFWDIflxirMcxkGD94cimmmrHJU3Ln8BUducjtSbhIcYAI61NBGSM/xUrRlm5GPwq7GKaIjnIBGa0rH5ArHkHn6VThAJ+fr0+lWoonVSYm4zyCaFpqa20sbKzDcCfu4/Gr8UqsuGx7etc/Arrypyvp6VehEpyCAQvPB5reM2TKmjVml2DJOexyOlSwSo0ZKjn1JrLEjM2CMqBzVxRlPkC56jmqi23cylTSNBfLZCHTnOQx/lT4yMkYLL0wO1UhLIsfQso6n0p8dwrfdbgjoa2Uuhg4Mnkdo1CluDwM1E9yzoA0i5Xj04qrM8pYYZcZqKc7xzwfXOfyocrCUCbzD5uVBHHOTUBuJvPKnBjphJB+QsR3BPSqcly8cy5Uj1zWM6nLY1jC5ckmJ+6cp/dqAHGWPyk9M1H5qiTKdPUdBUMxw5DdD0waHMpU76CzSKXCnIbFVy6swONrUhcEnzF3r29aqvIS2eCp6cdKzv3L9mtiV8EtE3Q8kelNVFjG0jK+ncVE5Y7CdxbOOnalWTaoGN2OOnP1oVk7kumPVQcNmqck6mX5RtJOBUwJSPr16ZprRIScLhgcgHtVvyNIJIWFMycnIJxirgiJ+Ykg9BmktwFbe2ODu+tTQymYySO2FDYxjvVJaGjECYl+YHoad9lBiVgPm6nHU017gR4BJIboTwKqm4YMWyTnjipbUXy7lRTZdDMpGRgAdj0oW5zKiKMZySagKMVAZiSPSiTEbqy5V179Q1OSfQrlTL5nAUAqCBwOaatw4LALkDj2qnKd+CpJPUiptz+X+8wpPQe1FuouRWJDI0jMM8+1RK0rAjqO/PNWYYgcBm+Uj0qKWKSOXhgEPbHNDWl0CSvYqpIwlC4yOnAqwkm1nDhRnpT2kjDBS2AO/rUIZdx3fNjoP61nypGqV+haBjZh13Y6VYV03gL1xxVG0ibzWaRSCegPf8a14UUoWJUYGDxTRlNJEJIHJHz+p4pbZWkYkgKOxp5jZzgrjnhjU6okGFB3uo5J6Cpau7slrQfHbHGOv0ouIcDEgAIPFXrRWLKrEA9QOuKguFEkm7G5ulW0kjnd7nP3ke99pH1qs9scAkDHTPY1rzRlrgDoenTimX0YSPacYXpisVZ3G2+hzdztj5P5Vm3UwwR0PvU+pSkFivAzWYZCOeWz1JqG+wQjdjrZSJckmtDeCnJ3Hqaz4PuYPQnOKsShoYht53dqlM74QuSeZKJGcsVXFPilw4KEk4GOOahhUsQ0hPTpinxjY5eMkY9aTZ0pKxfKspDNnLDOOlUL9HYBsgj0FSGZ3JLZHp7VHJIoX5jyeBRe5Ki0VFJJBI+oNQyDkjI4qxMCzrk4J4AFReU24K3PORih6jlHqV95XJHanwSYcNnBansgTcrDDelVZQVAIpnDVR0+njeuT0NXTAT7jFY2j3AeMJkjnrXX2MSyKGHpjpW0Pe0ON6amDBAwZic1rWkB8hmPOTUk1qUdipyOpNW4IGW2UbsKecetNQ11Nea6Ki4TGIyB396XBLDYwA9j1pQXV2yDkdQeeKgVwbnAjYEfwj+dHNbRm8YdQZpYtpIyCeMdatpcb1wqk46jGKNwLbHU9MrmpLRd4YKNuOTVK62ZMkrXsWkdJYwORxyM1HgqRsJx3A5xSFSgDbgFz3qNpCrbuqj0rW5ko32JrgPEpD7WHXdWZPOc7QCFHcc/lWlBfLPviLBcHGD0zVSWJfPG0fLjqT1NU/e+EqEbaSRDIWCrzkDn61A8rMThQO3XNWT+7dlYMcdKrrb7GZo8tuOTkVlJXKil1CUlwMAA557VEwG3PcHmi5aQEbFORTkQPEMnL/eNLlT2LUbISGIlNysOex71WB+cq67Rk5OKtrIMYGAPp0ows245HHGCaaV0rEtW3KLyL8qgEnPamkbhkjDDsO1O3eSzpINvGVIqF3YDK888570epDj2HSpnDHAA7nvSoqqoZiCSegpSC65OduKVmAAZQFXb2quVXuTFkkZX5VOd2eSewpJJEWMbZFGeQPX61Dv+bk88nio5gqnd6nB7/jRc2jG7JmzI3zjg8YHQfSmlo4sJwgyMEcimBXkBO44H3eelNWOKNFWRWZ2bAFFzZWSLkDhkDKQT0prxtKcB9mGxg96kMAR0aNRtI5/+tVowBlX5Rle3p9aVnLRkp21IIcxbUAJ5xuxV4sqKd+Ax6DFN5V1yAoUYyOlJKHV1UDeQN2X/AJVT90TV2MhlWR9ikxnPJxUty6RZcF3Yj65prFimMDjsOpNQNJlwQ3z981LelylC7uVwTK/Q7u+eKtIsiBSFXb1ORmiANLLlshBx7VdRCU2R7iDyazSvqXKXQbbziVGQgkA9RwBU6sADjhe+O9OEcFvEjHHpuJ4J9MVLBuyCBvOSemBina+5m0uhLFEzOGfj1LdakaJ94C5XPTA6in25V2Vgi7hx1zz61orE8oU4GfXt9Ktx5loYybT1ILZGXIHyDHXGSxqS4hYQuUHybh9avrDg/LhRjnv+NSQIy/Kfn3AkEjnNX7N7M55S1uYxg3R5Ay45BrlfEl35TEcbjxj09663UpktYHyrI2DkHmvMtcuGur1lALAdTnpWFX3VZBG71Mq+uPMyqknoSRUWDhdv3T2qSWEIiqvLMfxzQiYfocg1zGtLV3HqcHG3kntWhJzGvHOOtQIiicE9Mc1ZbLg7V47ZoO6LvYreY6g7uR0z61PCmcBMknqKkEZCYYDGetWobRUj81Ac+tSbplW4TcgHODxx61mvE8TrnO3Pet/ym80HjnnNTrZ+aD5gxzmmlcfMomIbcFQwXmoZABnJbOO/Fb7QBRzjHtWZdQEtlVzg/ep2sTzXM9truCy8+tVphnf8o2gd6tyKRIT1zxULpgkd+9COasrkOmXBhfbnjOcV3Hh+/VnEbNxmuFYKQSMhwe3pV/TbloLhME7Dz9KtPld0cDXRnprQGTKjHzH04qWW1EM0ceQykcmpPDs/2q1QhvnAGBWk9u6sZXALNxiu6MOZXRkpWdmc75B8w7up6n2qvLZspLkHjqw7V0M9tt3GMq4HBC1mFmO7HIHUHrWcoW3OyErlSNAy8AtjlsjmnpbKjM6McE/lVqFC+zd2Heo5FZ+SoPb5aaV1cbetisVdcqSdhPpwarTgAFGQnGeRWijsEP8AEoGPcVWYEdVJXuRx9KVkEdDJ3oAcqxBwxboc1MJnAAQHZ6jvVu5jVvmjB3+lVlhkmVkGUbGR7U7GqcXuK0olzvBBUdc8ipQ8vlqdg5Hy571nxxvEDjLMOcE/nVqCRmU7l79O4pxmKcF0JDlIyWwcAVQEiRy4OAx5x2qbayOXlJcZqvctHvATjPfHalcUYjpbY7hIj/Iwzj2piOQQQuVwRke1OhY7HDDAHKn19aaThwxxsI3ADqDTsm7oT7MguGXzEO7kDOPaqF0+JgI/uD9KtS3MbjO0nacHNQtBi6DgZQrtz2qJe9ohbbivI+wRj5ix7mpNpRlQlSMBvaoAA7BVBGOd2KXf5Uwfk7vlHtSuZpF6bbuD8Z64FVrj5hlTgFhTlcbiTnaO1OtxuXBGG+9hu3pVPUuGhCrlCNgyg52jqasRqjSKXyHxkexp8aADOCxHUgdal2sVUIRkn0oszW46SMtIvBOO+cYNWPkhjB83YWODgZzVWH/XZkyqjgD196vRFWTLjcM8YFUgasNiPmOF5ZRx6ipyBgq+3zP72fuimpKm8oq4IOfbNWDFmNc/ffqQKaVyWyhetGsy7SzAjG49z7CorZFZ3ExJcHsDWk9swYMpTcOFGOlOCCNgj7Hcfe29M1PI76mikrWRGgiG1IY2J9MdDVmNmU42qcDO0U6G3AJDSBFHJwSD9abLMiXISKPzwD8xUHC+mTVPREJX2Jfscdw4Z0G4Dgen4VZudP8ANt+oQg9M4A/xqSLc2393tLde9WGhcFSp2tyQTVKCaM+eSZXt7dUQEZwO/Zqt2jsFzJuXPG3OTj1p9muLcB3zIv3s9fwqR1jc7cDcOh6U+SyuiZSu9S5BGrbXQ8dMGpGUqGOQV9Qe9QBlDD5MYxwKA5yy5HPYdqt6HLK7MDxJ8kbMRzjcoPI+lefvGqvz8rsckn3rvdeJe1aMhwwbA9xXGXUQ+1McAYHBrjr90XDaxlTxhbhWAJKjuajVScEAe9XLiNmYjpxTVgwA24fSuazbN4WSHQQBmDY6d6uQRGRzk4A6VXjm2LtOOOnvU6zheRxmr5UaqbLsVssjquATjBrWs9PZF2hS2fSs/TJ1+0gkjBFdz4euLdLhHdASO+a1pU1J6smrWlBaGVp2gG5cKseCerP2qW90GSyQ+Yeo4rpNS8QWyNviXa4OOO/1rB1PWH1Gbe3yoBgAV1Tp0ox8znhWrTldqyOdvLLYAwB6c1lyQKAxIxW9e3ahTuIwK5q6uxLMQp4zXFLlR1RnJlWeBWXPBI6gdqpeUWOOKuyScHaMZ4NOt4CVJIwODmpFKWhifZ/Ll4OMnJz0qwqBDn5RmrrQkykkdKjEJC4B79KgyaTOq8IXpitzkk4PJx0Fd5ZTwzoJER+OSxNec+FlVmkJ4IGMev4V3unsFTbGOQOSOma9ChO1kznnFMnlQPIu08HggetULyJV2gR4kyQAw5P41rOzrGMIQG4IWop7bft3fKcHOTx19a3lG60CE+Xc5+QSxkZVh/sEdacd7fdOVB59hWpPDIke+QGXaOCOoqIjAz8rN1Jxjj0IrL2bizoU7oy5EIJYqSx5wKjZWi3knhvWrU0pjkOQATzk1VO4sMNhSeD/AEqWlsitSJkkDhWGD0x2PvURYLNjGWHQ/wBKmvPnYE/LgdexqDaGdVUgqejVPoNaoZLEAjSMDtHQelV1ARd6nJznZ3q477Pkfk56j0qvKVVt4XnsDQ11Q43KTM8kmArBT3HahkXaGVQp7Ad6lfexZANnfNJCP3fbjoe9SlqaN2Io8HgY5/nSOU5DDLAc1LApR9xxgHB461XulIcumDjr9Kd7GW7sUZliWZtp4PXFSKv7tVP3e3PQVDwWZj0JxkdBTwVEcgAJHAyDmpW+oTRUdtoymcE/lUcjncoPPPGacUJB5xs79c1H5ZkkjLZODwPWgI2JZA2VVsBMZbFWC+ImC8t/CD3FEyNlmIOFHFJGhKlhgt0OewppNGiJPOwDgkfL0p1nI7kZBCjt3plsqyISwJKHgelX4Qu3cBg+tNLqVdJEqqCwL4KkYOe9OgSVZCMgoOgp0KK7kN8vHPvTrWLa+8SAKvGDV7kpksZSJmLrwectxUySgIM/MScAA9ajuv8AXBsZXacKO1KYG4CkKrED3oUbaILJ6sspnGAFUhcrgZwRSw7xKS6q27pgZx9ahjeKNguGDKce5HqasIzorsgL5OCBV3CxZZSXC8ozDc0hI6dh7U+zgWKJoU3YkO9yOd1MhI2gXGGQ8KBztq62xGDRb0QH7zA4/KnHuRJ9CS2jQKxRmHYAdTVi4j2IAx2oP++gapXM0sZEibJCQMyN/D7LionneSOMlEUjkn/61NySVjPlbdy5AirmUBt7nqepFTsh8wOpAHfPWqEb4kRS4ZsdR2q4HfYASpCnOR3rLnWwpXLSthS3QetNB/h2jn/PNIrEIGC5OMfjSswWMjjPf2pqV9TBoxdYU+UWA6nC47H3rk74Ktzv52sOc8DNdjfSIytkktjpXI6mu+M4VuDx2rnqtMqCd7lORFOGyCKrsqnKdjUkW98R7TnsxOAKki02VpA1w4C54C9ayV3sU5cpXe2GBgjFV54WGQp/D1q3qifYkzCxkJ/hNVbe5chFki2A9CfWm1Z2ZcJ6XGwSPDKp6YrrdGuRKu3cDxzzWJJAsiZxz2FLbM1u2QSAamMeWV+hpKanHzOjvApJBPy1VmuUjjxnGKz7i/yuN3NZNzdM/wAgfca0lNbIUE7ai6jemaYpGSe1RW8ef4ePWi3gwd7E80lzK8QKxR57ZJrJJrVjlNbIs+T3JwatrMETaCMmnaRp4uo9145IxnCnFaFzo9kIyI3cEj5ST0rVU5NXMHUjezMN3yx9O1KQBGQOcc/Q02Sxa3dRJJkE9u1NOJmWKIEuOtYa9TTTobPhRSHdiDnHbvXc2kbLHGSQM8t2xXKaIhiGFGAODmulinAj3AquAcj1rrpNLcxne5puWK4XOD0IPWgMxKpIQFx0Pf6VBYTZiztPzHBX0p8n7vBbBXPftXVGXVEJdGOmmjC7PmTuGFUTCQwljkV8Mfm6ZFSeepkUYz1GR1xS7g6hdwcDgY4IpuSlqzSKcdjNuYlmWQ5MfOMMOtVo7VoUBVgw9Rg5rTc8MuBk8bm/zzUEytCuyaPJwfnTpUOKepspdDPZkPAyTngGoCpHzDCjp7VL5wLM6oAD+Y9xVa6cSRAPuCg5Uis27miT2IxiRyxLHHT3pl75fljOfoetTw4hUnG4DsTzUF0FeNSpOT074NTbQPtFFd7goj7QcEe1WGGYuo59KpPmOfJBww5I7UPckKFHG2pi0tWaTjfYnVzEQTyB1Gar3dwJCXU89DgcU2Rj5XT5s/N7ilijVoyRzu4BPGKrchxW7KTgKzY+YH+dNCskmS2EboKkkRkQ7hgDn69qSNUebB444qbX3FJ6FN5Dwu40vm7YtzKfl6GmwlGlO7gDpU06BlXA4xyTQu5CEhuGlAycfNwPWrgKjI24U9RmqCEK22IYyc8iryZMLbjg9AMc01tqa2sCkqybMYYYNXFYbBuBBI9OlUpDG2wqDkDt3NS/aGIKkZJGRkdDTTSKtzGijRlSrqQox9aY4JcFXyAc9O1VY3diSTgAc5q9GqeUoGB6HNNahbl2LMTrvVj931oLKrFASec59KglZUU7O/UdaGHmIMnDYzjPBFU2+gKJbjJmmdWUIwGM1KvPG9gi8bRxn1+tVIpPn3OgYe55xWkYSsXmRR4x0HvTSbWgS00NC0SN1Hlx7Ff+92I71YWbCyKis5ZtjE88CktpdpDRI4Urkj+8fSoruXcrBWljTGQoA610XsrnNZt2ZSvp4ozG0HnmcNtYOPkA9RVOG4fzHLMZPUEVbaVfKKBA+ecnlqbBAOQcjuFHf6muWbd9Gbq0Y2Zes1VwdoXceCfar4ijjX5eQOpNVbZFXKqMN146CrD7nfbkbV61PQ5ZPUcCWYPkqvQD29aqzuFIHtgU+aXe4AwAP0qlPJgkDkjuKJNLYha7kUqlQTnJxWdLAGQ7up/SrUkoLbSxLHqaguHVQCOcmsX3NEmYs1sYyfs7MhB6YzVdxeYBGNw6kcGt4xqz5IODUjRjhQoO4dKSjcUpJdDmWjlmI83ls8Y71oDT1ez2sMEdjWklokjqQMEHn2q4bYhSoGV6E1pCHczlO9kji/OuLKXaV8yMcD2pjXYfJLbT1ANdJc2DzMSVAboOOtZ82kDf+9jzgZyB0qJQl0NIyS3MZrhWyMj3oDI3/LMj3xWgdNw4CplifStbT9IPyeYm589KmNNhKp2M+ys2CI8+SSMgegqee1GwEgew9K3WsZCArAcdMUPaZiLHDEdq6OXojO/U5lbswkoi5I7UiXN1K+0xnavbuK0fsSiVpCBnuO5qykUZm84DnHFYcr6s1vEw1hmuW2zsVUdMHvV3T7MRZKDGD3rRkRF4Uct2p0IC5BH1xRZJjvpoSxbkJxjHepVu9h2gkg9u1MdQy8HrxR5AYAk/lQ79BRav7xuW0y4V1BAIwRVwjzI+ueOM1lWLFcLn5uwNXopDGSMZUn8q3T01M35DVUxxndwQfvAdajwXw3Ug5LA4NWbkmSI7Dw3TmqCHDY8ttwGMetaXV7I1hqgzuZVdmVCDgkf1pZLn5NoQlem0/wBKED+WWjHGclD6VVkLtvZGBUdBnmqd0i7XK88qh3ESEcDjpxURhBBk2kKeAc/0p0j+dGOCMHsP0qKUZQ7/AJVI69xWfqaW7EDRyRkliNo+6R1xVUqImJBYjOc+tTrJuOzPA/iqnOXeXbztHc9KzZcU9iwtsjMrhcIRyapXSxxyMRhueQKt2buzODnaOPrTLnZu29D3OO9WtiLtSszOmCybskr6U2IngYIXdz7+9StCZcliSF/Wo4kkWUlzwOBipd0y76EknzMFbJIPHbFUREsch2yGTjcw2kbGz09/rW9Gj3OmRQ27wKySM0qSOEJJ6MCeoxVbWZEeWNTIk04iCzSJ91mGfzIGKbjc5+fWyObjJCqpXknIPetF4xtU7jx1HbFUWiG9ZV69SKtZMqbcnpkH2qFpoC1sxWaPzcqpBXge9W4NrorNww6VFCgEeGA4GM1NH8qDAB+tVY0u9hY0XcRtKknv0NPkAMgBzgdcetRGR1cs3ftUE0778HI+XJZe9FzWMWWYVEkmC2B05qz5ROz5s45J9KoJMuSOWY8/SrVm4lQcHPrTuti7NF1ACQFXjvk9KbGheU7htXoGzT0IWMggKT361UiklRzlgSei0N2sEVe5pwIglAJGO4Irdt5gU3FwWOFORXNJdeW6sQC5GQM/0rVt50dsF1AB4XGea0hNLYyqRfU03j+Td5ksa9gvf61XVJuJJG2DqMjk/wCFOYEEiPBPUjfUgEkwDNkdiT0FVJ3MU7Ij8vLlgd24Z3HjFWYYwv3lyvGWHU0sUeHwAF9z6VKCuDliV7nuahomU7huAUhB8x6ew96bLKEjAXJYelKwKZOMEjJzWfPNhzn0+lZtuxG4gm+RixJJ9KozzbSzKTk+9KZQ3yjgg1UnxJLtwxxWTLUbMI5QZCT3qZY/MHPQVXCMFOwcDtVq2y0eG+X+tTFX0JnO2xIuF+7gE8HPapIyDIoOD25qJSigjg06EBtoxlvX2q9jF6lmEBRx0zgEdqtRJvIbdge/eosBVKBcDr+NW7RPn4we4OO3pWkexPKStZJIUIYKRyKJ7BcFlwcjp3qcZDjaQR0yOlSNlm+6Ccd+9dKs9LByvcyRZYwWAYn1/pV63t1RdnODzkLj8M1Mm1pW3IwY/lUk0TEB9xwB0znFKMUtRWK00KNEAqgc4qnNHuZkOCFHbvWkFwDuJYds8VVuwoYE5Jx17VE31BIymgC53gZ9ap3MBVgFI2leMVqyIXUEjIxk47VWnQrGuR83oawkiotoyDvZiSee2e1Ikj/wnBPr3q5NGvQL15xVdiqHjJFZNJGyndApZX+ZiAR26Zq1DONnXkdapySiUKMfMBwaIgVOMjB7nvRzWZW+5rwy7ssn/wBetSAiRAc4bNYNrw5OcLj8617WVVY5+6eCRW0H3MpeRa2hTgnajHr/AHTRdRq2cICRwSOv1FLIUClQxIPX/EUW0owRuPyjPPcVukk7Am7XKkm6I4MofI+V+nOO571mTyBYJHvMxkYAKAHPua17wtHIfIK7ByUbv7g1yuubcACOZpGOdpPQZ/WlUbSOygud2JRdMx3q2QWyFXuKbI58sDJwTyTzmoLZT8u0bQepHaku5DG53g7TxgVk9rs25VeyC3I8xgOD1OaHkXzT8pK4574qNRuU7Rz3odWVMhTjHzE+1Stga11JYJY9jMh7dBVKaZiA205zwMVFHOwdQcL7DoamXyypDHBycjNUndEONncbC2+UhmAU9waTAVyAcGk8kbG2cY9KRY0MqSlSQv3l6Z9qSbsS7bm1bRSnTontLSKdizCRnjDEkHgDPas3VY5w6LcwpBIFztVAoI9eKkW8scELYvk88XBrOvLmKW5DwRGFcEFWcvn3yaq+lzmUXe9v6+8ox/MF9AOAKVP3MjRv90+vWoWZgpwTnd24qWRwGDtySAOanzFBlx8FNqjb2BoyY9xOR061Fakgljy386ezAyNtXOeoNVc6IEuN6F5AVHAFVHzAyjOQTV0viIAj5Qe/UUyNFbiQ9emaTXY1i7bkfkJu3h87uwq7bJycbRt7j+VVZXMYA2g84BHpVqL93GdxJJPB96a0Zbd0WwOobvzzUM0OZABh/VRUzDfGpYAnHUdaah6kqQPXNN2tYUXZ6CwRM33ky49e1WLGeJJ2M0bHHfOM+1EUmYSq5bH3jU0WNyZjVAP4gBk0krbA5X+JGiAqKThQDzjOABUizp82wgAn5Qn8XqPaooIdwBCBAwx85yf/AKwq3FEmd20bv73b8BWjTOWTQsSscBzkDj2qSPAG5OingenvTxGArbCdnU5NRO4RMquEPalZ7sycrkcsuXOScHnFULhi+5jkfhTySTz1xwKgkf5csfYCsZsexUhVkB3nJJOPpQRzkt34z1qyriMbm449KpOxMjcdRnPpWTQ+a7Jo3AzgjGepqSJ/MIYEbe+elVC2ANpyQOTiiKRmYxgDI6mmnZkNXLifNKwIxtH51YjKKpKvjjJPf6VURsLsbA5yxNNlvIwfLAXHY9cUcyW4kmy+kzYR3XgfdGeBVuGcqQ6gFgPl5/zmsS1uowzsxDY+6KktL8NLg5VB09aSnazua8h0wlV4wSTn+HJ4z6VctmRoA0hCgjBPpXMJeq6YU4UcEEZyK0E1CNhs25YjkCuyFZIznB2NdpBLGwjkUODnHqKV2OduF55INZ8N1tQKzxgDk8YxUMl3sbIk+UDgkd6r2itqZ8rvYuOHU4Y5J7f1zVS4ViMx478qeapXWoq020+uBjsKiku9rZDjBA/KuadRO5p7NlnzWVsNtJP3snmq80mV67sHioGuuHZlHz98d6fI6MgIA55xn171nfQlxEk+c5UcDtVdwoJ/uE9BzU/zBV6FeoOefpVa5kWQtGGXcOSPak7WuQtBNoiJ25B6nvxTgQ2cc7cU2A5jIYgehzTkAyNuc9MGjsUmSE7W+8AtXoRuRSmSDWdcwebGwyRgcGr9h5ixIiYzkDJrSGrLvdaF0iQqF6HHeoS5VEaMn5T8o71aEbBfnO7J7VA0AYOc/dwRj0rWUXsOLRNcOXiRh/q34I9D3+lZkqFozgK0XYOSCp9RWhbyKXKHoeuehqK4VRkMAwX3obujSMuU5+UbF2EkljwR296ZG/RZMMenPFajwglidoQ9j/Q1RlhVRuUnI6nrxWbTOlVEyo0hBbaMY496exLxEDPHWpFgySx4HY0yQhJMA89faqjFik1czpieMxjcD1xUMreZKqlsDrgVemAZ2Ock1RaPEnm7Tnpg96mSZaasXkIEeEIHPJp8oUBQucnrUEHyqwHJPb+lJIDhSOCOvNVfS5ztAAqsGHJB44qpeRR7dyPMZero6AAH271u2t3bwWULtLGJoBI/k4yzueFI9qytUuRJcW5adLidYwssg6M2c/jgYGaTszHmd9jCQ/vhznI79quooZF3ckHuOtULf59rgYbAwauw5CZOcDr7UokJlmH92MdxxUa53lvfnNIzybG29c0ivIduUxnqKq9zeJOW6biRnkmnxMQfm6gcEjvTQBtAxkjrn+VS/djBPLDpxVWNk9B0z5VCVFT27BgAhx2waq5Lupxx34xzU8LMjFZcYzwRRe7K6FlUKgufumlilUlsHIHXiq0zEP8AKzEEcqTxSRIfKwwbd65qfIaXUuxb2QGIjHTHQVPAy+auSoYHk9cVHaLuXaRkd89qnSNFkygyR3H9aeu5Mn0NaEo6gByxbJ3HvVqAOFLPuOB6cVmW6ukjFAWHp2rUtnJwGHI6j1rRNPc5J6bD2+5tP1JqpK25geWGOgq3IWfBBwpOM1VuN+OPlUcZHU0pvsZXKdzMBuVRgA5LVUQBx5j5/wBlfSrE4JT5gAvWmLCCo6jv1rCzbHzWRBcEqgUA/SoJD8oU857VbuCpOR26VTuZ4wyqpUEDk1MlYSu9hkxES55we/XP4VW+0qkvyA89MdKqXF8N0jOwCrVP+0kkACAtIRha551EddOi2tjXurhRGXdsKfX+VUBJyJCSyjJ684rNa4nmjYN8zdR9PSi2z5zDO8sm4j1rNuUjqp0FFasv2moCZpCFYAYwKn+1ux2tEyseeD0qkjxQoxVTzjDAd6txSszlioKFgN3Qjimqctmy+SO9iSKdtqbdwJ+X/wCvUjXFxHcBydxHOQai+0r9kCxDc4Q7jjgZPNSwwPPN5bMTgAq3Qe9VySWiJaXUkbXJZVZYgSwHOewpkl/PO4QOFOMhs9faomtxEjyeYoj34baOcZxSxxwxTBPlc7WI3H8RStPqJQgtgLToCXk5AJwBTU1BScSsAGHO7rU6Mswi8sEsYskeh9aoziF+gVl5CsRye1DixpJ7mrFcNsXBz6D/AOvSwXqhgGGCBjI5/GsuOVkZVJOFO3B7Uv21EmO8ALjjHal7S25k6HY3nkZVUA9fyNNWUFCxA57d6yhfoyh+nGRk81PHcLwTwR1zVqojlnTaWxeDEDIAKk5pVlKS7txOBzjvVeGZPmOeHGckU8DIUgde47VpcxtY0EDnk/dx0FWIdysBnA9RVCKRkQ4POB3rShG5F2DJWtUyb2RruqmNWBIO37o7HNQsfld8DHtTgNsTKAWz1560sYAUBgRkbRz39xXUndhBlPou8EbuOKjMy7iGIxjGakvAy5JRgV6Ad6zpyZFyBsIONp71ElbY3irk0nyx/wB1R0JHArNllCSONwBA7d60omLw4YjI7VTuLeHDFlwfUVLTtdGkJJOzKkdyrBlLY9BUFwdiPnqf4venQ7JVO05IOMEYNWHgJi2kgnrilC9jSTSZkxyfNu6N2BqSRhtJPOeG/wDrUTx5JaNSeMEelVrdWYgPkMufyo2Vit9S3ZE7cbRntTbtl5VeR7d6bG7cBFxtzz61EqSGQ7ido5IxSu9kYta3NrRrdpNPaO32kskonHG/dj5R64x0rM1uMiW2Vwn2oRKJiuMbh9O+MZq6sNvBp8ErWSTu7Nuk3MMYPAOO9JfQW7wyeXatbOtutwX3E4ycbSD69RTdrWOWUrSucnalfL4z7E8VYtlk3MWbAPbNZ9pOPLGQCnvV+2kKzfux8hHWpTQkW0fcpBGDn8aUZ3YZsD26ioy6xtkAEAYzUrYYBhwM4Jq1qbxJSQCCTntTmdWhOw5fOfpVdUEj5bqpq2IOcnjvxRdmqaGRlnI3KauwwhmBIz9elRwgL1OMcE1HcXEsRG0FlHQA07q2pavJ6GkLdcnoG9OtQshD4Ax6Z6Clt5iygj730qyV84btxBHYmrdnsK7juPjj2KoJ5PIIp3lOOSeW5wKlO2ND8hye59asR53AHAP8JA61LVzNya1JrdSgGeCOD6mrkSpvHXIGSPeqxI8xCpOehPep4wxJLMCewp7bHNJ31FkcBdu3rxj0FMmj3RgZ57H0p2ZGfcfmA4FSkbkPGPU+1QtTJszZlwpcgBQMVX8wD58DPSrF/KqRBMEAHvXKa1fGKUAyLt6fKeRWcpcppGLloGratHBOAcn+Q965vU9YDz5g6Yx+NQXTCaViWYr6DniqyWqJukLhEY4wTkj0Ncsuaeh3U/Zw9R7u1yD8zHj5vSpII2R0ZztdOMZ7j/61FzJDaW4czRPu9PWqv9oWuCPMBLDJYmmqcY7mirN7GmZAJBxhG6Y7ZqW22pIAr43KcHOMVgpqMcp+8rAcA9Ktx3UL8lxkHpnoKd0noaK7WpsxoTGDIPkLYP8A+unwBEuA33wS37snOPes2C+KAgSBl67SeDSrejdlWQMp3qP6VV0xu5oStG0BjCyq2CMqep9xUlokck2DNNA5QFST6VkS3qNK5k+653fLwfwpz3oITEhIUYXnJFVzIavsbXmXJMkRuY34yQRncKi82SWweVlXcAAGB5GOMYrNt7zyml3HtkHFNtZwW3OSI1O4getJtBr1N5mCqoCoQIgCVJyPrVMOz4VevmcEH36fWqpvo3bcN2Au0hRikeR/s6Kcqu7d9DSaRN7E/wBrLTPuG358jBzkd6o3M67nCE7mYAf7PNEksUS79wkZuTgHrVJpCzEgDcOTnjFRKKKU+pZldgCi9RkBs9amF08SqgdWP8eazY7sCRcgED16ZoUvLIezNz9Ky9mRKae50Vpq8TBF3cD5TkVsQ3aysvlsRkdu9cOYmVflIKjhsdakiu5o0AQkKe4oUpROadOMtmd9DKpXkZ5xgV0GnjneOgHU1wmh3XmMsbtwO9dpZvt2knIxXXTknqcdRcuhtwuocbAMYzmnlVdMLkMc89c1TifqGOAehHSpEYrI245PQjpgV1RkTFDJo8oBGAWUcg1i3aSGUHPKnp610T4SJwgwWI+asyaI+a/HTpTnFNG0J2KMabOc9f0pGdQ+049cHvUsue65WqzKCwI5b19Kz20RW+oxoFU/Kny/ypm11QkHOD+NWyrKAVJLd/SoJFYzMFbAY/nTtbcFNvcqtOFJyByOgFVAoEhKquGHJPWr8qBELOPu1nTMBOp+UqegpPTc0jrsTmFdnuO+aqliEbnrwKlefhgw/Gq1xG7FdhIXrQn2JfmbOkxLBDGftN0ks6PIqwsApC+ue9Z2q7URXtpp3guEEpMr5Mjcjn6dKmtJfs9hBJcXvlKZGeFBFvII4PPofSs/WrhJpEEcwkGzGFi8sIPQLQ9jmd+Y5K1+dCiEnB4PStOFjlcDhf1rHsNryL5bEgdzW6Ap+aMEkY61lEIyJpV3xlh+XpU1s+yPByRnkUsIGPnUZbnHrTzDtAwcA88dRWnmbRl0LELK7fLnnvVpCvl8nLdCM1QjDBSU79DUyyEkkfezTuWi0rx7yAepxj0pUZGLIqhjUaZ80cZz6VpJbAIrqo3fqKpJs0cktSmCY3Xjkn1q/Dbu4LEjf6E9aiNruILcnPHtV+LEZUHkt29DQlrqKctNCa1RD8jjOO59anW1WFi8eTnrUVtHI82XJGDwO1XGVmdcnAHUjoatK6uznk3cZIAsQcLz0+tTQqwUe/J9qdKoIQLkEmpI12qASPX61ElqZNjCSFYY5NRzThRtYjAHTNSyMu4hjVC7eNSR144rNyshJXZga9qiRIxGT2IFee6s11ckvI3lEcfSu61C2aaZpGUCMcD2NY975MdxGrxrIgGNmODXNLfU3iuiOLEVyys32gLIuAm1Tz71B9kvZEBkuO+BgV195ZoYgV2hwM8dqoArGp8uNhIUwcc555Jp3SZpHma0ZiNpkKLumZ2wwHPc96HsISSFUhVGOO9bdzPDNpyEnbMhKlR+YNU0kQoUZcLgkkdT6UpSXc6KcJdSGHT0MW8AbQdpx2q3BaxJGQdvHbvTbKXKFW5APOKtM7BUIQkjqcduwqeZHWo20FXT1K7ioUD9aV7AxocJkHj8Kuxea6DaoY7s+hq2kRYwp5UihyRu4P41aXYbVjDaxUtgZx/Sols1Kyqm75O+a6O1srl1m8hWwvO7b/D3qKbTZFu5woZcAHCjOecUrO2xHu3tc59NOkLqN7dMkU82MmAMscnFdPb6W7XUivwsaAlgCcZNWY9OxbShiPMidlIYYJx0xVKDaE5RXU5IWRhD4Z8ry3NK1u7qXaaTDKCOeBXSpCsksJkQAPFlnPQGs94tsEARAgYHIJ7UnGw1ZmBcWThGZJ3BTHGaqlblE3pKHcg5Drmt2cYt5Np6kdB6VnXGSUCg/dzxWcpJEyp3M2KWfeRLCjAdcdqVbkIGdUkAU/NnvVpEKMS6nay5HvTLiMlAuAvORgdaFKLMJQZTbWBAjb0dY8/ex1FNi12NyQAQD6g1YWzV1YOCd33eelOi0lDCQAATyDii8TJpoT/hJYYpl8nczAfdUYrtPDXic3hKSIRIOua5rT9EilY7415746Vu2OjpApKgiYHKyBug9CKcd9GZ1F3PQ7O4EkYPUEVowY4AOAV9Ohrk9KuZbcKJwAp4DBs/X6V1Nq/mKGyORiuqnK+5g9ETuMhd2NtVrjLR4Ruf6VcaPnk9R+FVSWyyEDI6+9bMSZSljb7PyODWU6gcZYEHB962Z/miGBjB+97Vm3A3Nhe3JJqGrsuLBGOw89u/Q0hHAbHI9OtMwBjPfsamkJCtjsc1VxbFWeQOu0KWJ65rPeEO684Aq5KArBieeoHpUErDaWyd1S3c1Ta2IgnzEH7vWqd9OyRsQec4wKuSMvljruIzx/WqKoHm/fjcmfmCnkj69qTfRCv1Zo2K3J0e2+x2lvOGdjJ52Cc54IBPAxWfqYmF6q3MEMDGMfJEAARnrwetTyvpAGRYXBxxxP8A/WqneG2kYm1iaGPbyGfcSfXNDOZu72OHsCMoAo2iuigYBkwflIrmbNhuUEcn8q3rRj5YB/hzgAVihxNuDBYHcMqe/epnOCFbGelUrV8t82SCOxq/GGAPIIIzzW99DVD4yXVgRjaMfjTGbK/KCCPQdakBXIPcjjnvT4wFbay/Kw9elNK6Ki7MsRMDtJ4IGMmrC3IUMM57iqLNtXjOPbmrNvCG2uWBzj8apPU1st2WredmYN/BjIx/WrsMsYVmI4boAKrW0Kq53dOwqfcj7o8DPtxQrkyab0LC3ABIHA3VoKj+UrkqFBPArHtkZbgjHDDPI9K2LcGVFO/GFJGR3qlcidkPkLGBdv3gc89adk4A7mpUjzIrt1I6EcGlZQikpkjnNQ092YSaRUniIyGcAelZEsieYwTp71c1CXdJsyc45+lZ8m0jaOcHrXJN3dkNbEVwu6MkYArGvrcu3Axj+KtlmGQMHb2FUpyWOMcL0qHsVG99DEntZkQv8rFyQOeaz2t2dVhb5WAzn1roThxvx8w4HFNSMbtzgE9AccioS7G8J8pkppKyqgAAY4yCMDirMXh2IKA45yT0rbiKCUIQCuMljV8KHXgD0rSMIsp15o5qLRrdNqlwOx46c1NNp6CZwigxkdvWuhS3QsocfhVyGxTkkYA46d60VLm2H9Ztuzm4NPjdDuARwgBzzn3FWjaNC8ax7Wizk966FLCPIAAOeCTUZ08AlVAznHFaeyYLE67lO1DQoo5TAKkDpjPSkupZdsjwuoeUbWVkHQnNaDWIKgxljjrx3qD7JNlgn3T1BqnFpWM/apu7My8ZppWkXKB1CyEHG4A0sjQryEGzzdw3ck/jVyPTpJZDv4BOMVdfSdqrgD0zmpUJu7Rcq0EjnbuEyKseVUEEDA7GqjWH70KTmNQPm9hXYHTMIGYbSP51XOngMx/hHU8UTpSvqNYldDl5dJR1PlN7k4qq2ixqrnB5AAPpXaC2QABEHI6ZqOaBVBVcYxk+9ZuglqxfWZHGNpasAoUnaD0HGKrXOlxqEBGDjtXXyOkagKB07VRuhG7plOo7VjKMUL20mcvHYL5TBI+OnvUlrZMM7tvBwB3Fb4hVZRt5Uj8qY6BeQoyTUqIvaNlG2i/d4TlVbpjHNatrGhwWwD0qvBGjlnQ7fYd6swj5uwOe9UrrYzk7lyK0j3Ddxk/gRWpbq0LDYcp1weorLgkZZkB5Hb2rVScSKdxBIOa0i0ZtvqXklLgH06Co5MlQQc8c0yFwyls4J61JGA7EAkYHQ9zXVFtoRBKdsPLD5umaznT5RkjcT1rVvEDABjgAAHFZE7lc9eOATQ9yolKZ905UHpVidz5eQMkjA9xVJwUmlfrxxTpJcQ7hxnpUx8zSUVoQXjsVwmAxH500Z8sb+oGP8KWMg/MePY1UdpATwMY79qdir6WJXkKhuOvU471XkYfK7A+VnD7fvEe1IZeccZPGPT3qFzvGCSPXHak2Zs0ba2s7hWNvbapIinGVCkZNZ2roIJ0SOGeHcu4ifAY/l2rTs7+K3t7NDO6IhkikUA87xw/Hp+dZOuzo0karMLiaGEJLKAcMwzjGeeBiiWxz63ODgAG0oT7Vuae7EFG+/wBvpXO2rAEA5yDW1BLh1dB26VgmVF9DesUJdg3TtWmoVJNjHk9Pasq2II3Dr0/GtGB0dWOCWA5reOqNEwmDLJIQMDvVuKVZIUyO3ekKbv3bZI9elMRWUgDkLyBTSaLLaLtxsPB6GpLYGNcEE8flUKAONq5CnkCrasY0wfqT61Rd9LFm3f5lJOecUjiQzqwxtIwaYhIUrH93hsE96ttyi7R82KFqrCvZjpH8lFCEMQegrZtSBDwQpxnn1rMMSuMMo3cfjWjaEsuyQcYILY6Grje+pM3oXd7FecZB49/pVW8m2RNt60+T5UTbgcYyDzVC9lCqD69vU1FWVkY2M65JD4GBnk5qB5NvTn+lNupWkLEYJ6cU0PvjZsdOma4rX2NVHQcWyQG+8eoHXFE0YblRjjGagix5wO4knnHpVo7iDngnoParSC1jPnj2YCgkevtT0TAXdjGOKnuUZtq5+UCmQqQOTkelQlqV0ESHdIM4/DvV6AbAqkcZ/GooFBPPb07VPsbzN68H09auInroWQDnJAIHI4q5Ed0mGznvjtSQRblyynf6ZqREK4JOfb1roiramWhZALRsUOD0NSNH8hIJPuKhViH4GMdsdKsRkNk5z7HvW0WS2JGp24Ptkd6Ur5hYj7wOCB3FLIduTubGO1MBAAIzt45p3sJK+opwrc/K69m6U/duB2Yx9KqmQMTvVlGcjcOtW4n/AHRbBPpjtSjNbBJWI3kHmKmMjpnFQyou4ZHAHG3vU5BbkcHPBpMjnPAzjjvQ/MEUwvzhSCx65/xqPUEHA9u1aHlblXB69P8ACqtzGWUA84qJLSw09bmPNbLkHkkDrVV4dwJPBHQ1rXC4jMY6g81WbAG3v6e1c7gr2LTZkmPYxJPGKieFnHynPH61pTxq6lc/TNEcYVSCMDGDjvWfIkyueyuY0CtG3c1djTO4jJXGfxqw8SsCR8oHeq8RMbMQfkzniko2G5cxKpO/Izx7VKsmxt2cc88daikU7srg8Z3UxWwoJ6McUOIrGzbzeYMpwD1FXvMPlHJC4OAR1rDtD5anaeAcketacMmQNpJJ7n+Va0pdxPyHM3zKFIYdevOKoXAUFwcn61pSJGEbAA29CKz5nVxt4yDnPc10NdBLyM55kUZYDHY1XlYhcN0PT2pbk4SSLI2npmqhdZAACSP61Jty6XIpn+YEHAA/M03zP3fzEAEZH1p1z/q4wASDkVEF2xsWwQOlLW4N6EMZUZBJ9eRQz4J3AYAwajLbiSOSwIpYfM8xWTBdH4JGQT7ikZSL6D7ZplvBBNBGyOzSRSOELHPDAnrxxWZ4nmSWSFhOs9xFEEmlTo7ZPfvgYFbNq8o05JXuNOgjZ3AWaAsx55xx0rN8R2cjoZxPZzbIld0gTZ+7J4YDGDzxRLY572Z53bko2MggjpWpCuxVDDAIyPpWKhxtbrW3bSb4UUjgVzIpbmrp7tvCjuODWjHI8cwK8r0rJszwN/VDxWgH5jcdCcVrF2N4u5qeYd2GO4kZqQ5DZwBn0qtb7ZCFZgrDvVsM3kltoyh4z6Gtr31KLFsUI3Z+bJ+ZakSRSTuGV7g1FCCMAA56g9qeU3OzEYI5OKfQa3LMT7vlICgdx1qwrnb8vDA4PuKzrclpQ23OO3rWgF4X1ByKhFs0bbcwywO4Y61fgJDqvA+o61TtZNyjHOR0NTiXcemB0NbnO3qTzsuAccD09qyL1y8wbBCjhM1ZnkDZbccZyTWdNJuz83utc1R3BIpTsDJhW2kHP1pssjFQO56elI7bmBIxnGeKepQOWOOO3WsrXNUOg7ZPzMcDParYQrncSecmqn3mDAH61ciPAHU9TmqVtiZXHS/dI7Acmq8ahnBA461ZIDHOBUsagKFA5IwaLNu4J2QQR5YkDmrKwAktu+UcimHjBX7oHapLcEBnBOTwD6VaS2Juy3Adhx36/WpzgnHQnkcUiJu2Y5JPapDHgDOMnn6VulZGb3CMEr3HPfvT2bYRjHPp1pRjBIywAzx2FR+avKqoY+melPbRBa4rrjqCNx/GlVI1AJyDnrjjFKcFVJOGHamiQlwMH5eMetK9mUuwrxKW4J2c5NOVAANnAAwMUob5MqAVzj61HGxLlXYrliT7f/WpvRitcm+Xj+HI5PpTJTtOM8Yx0600uGZUBAHb3qQjcEAySMflTvoK1hiMoXcc/wAqhcg5K8kHFNlUyTCNycZ7VPMgyqj26Urt3BqxSljG3jlu+elVNh3Lk9G61du/lCjGcmqs6uQTyB/Ks5DKtxhHIAzzzTNreXnjGencVO0bGMbuR1JoUhFJPHYg9/pWTXcb2KrLhdv8PXJqGSPDDAwMYFWZSASBg8VXLZUMcjB6elS0CEwNwyDuxj61DJ/qWOOnX61ZjzKgf2xmoZMYaMde5qrFJkcFxhdw555FaNs+HBPKEZOPWsSANHlW49K1IHxGd3XAFTHQcka0zM6j+6cnisiQgXAAJx948dMdqtrI2wK3BIyOarXi/OQpxjv0rZ3YQ0Mq9DscJgZPT+tUeIpRtbLH+GtK6TeRyfl4rKcA3BbsKTZsnoSyZLDBwo5GahYFQCOcg9fSpJJCU3IBgcY/rUO8Y+QkkjketF9TKWxWyVxu4KjjFLBvEIBO3cc8etD5J3/wsf5VJIVWJiCAT04pESdzRsdt1ZxG8hi+zRlhFK0/lHJ5Kjrnms/W7me3NxbNZxws8SxRsr7gsOc/Kf4snvU0c9nNp8UF400LRBirRoHyCcnI7HPes3WpSBaGKKRLaOHbEZPvOu45Y/jnih7HO9zgbc/ugD1HStKzkG0knGKyocDA/Or9ufmbgEY6VyRZZuWDZU5OWY9K10VWUDoOwFYNkxXae4PSti3nAbBHyMcA+hreO5ojVhRQVbOCRipnykn95cZ+lQQkD5TyPWp49rAsGxg4JPStrlJu+pZt2G3j7uMVZXbgc4zxmqNs4O4gnPpirUZUqEIxnj/69NMoltmG5s4BzirMYdXJwdpGcdqqqpIJA/3qv2RcoysAMd/aklfQJOyJYZwkpUAg4zmp3d2VxHznkL296rNDtfcfvL0PrUnzLtIYhsZ4pttKwXXQjnmjXcrnJXB+tUZJQzYJyD3qxqEW+MknJ9RWWVJ+QnGOaxadxqzI7lmwQnLdKeg2gPwWPX1NJKRk7euKdCS0Y6ErU21NE9C1GQTt5x1PtVsAMFHQ45NZskjRROyDOe2KswyjYpIwcDPvTI5epYjBzgHODzV6NSpDA8/yqOJAMHHtUsG44U4Jz+VaJWM5O45pflOFGO1WLUFlGMqc4xikVUbPAI9BU0a/JywznOAatR1Jb0LVvtQsq5+lSmTefmJy2cHHTFZ5uAuCpJGeQO9I10VR1Lkk5G3H3avmUdCeW+pckLKCUJxxyR1pUZYw6pgbv73Y1kS3oUBRIxPvVVr5i4CMQvUnFZOrFO5qqbasbxmAx1IPXI7e1MdgrAxk5z6dfrWLcX6hQC/0z3qD7QxGVJ29cZ71lKtqUqTsdLExG7cxVs9BTWZd23coYDGfUVzaX8oYjcVb61C17yS2WI647Gj6wrD9jI6Q/I5IKgYwCT0NSwuyktt+YdOeDWBFe+ZhWY88HvWhaTbScsxxxz2FaRqJ7ClTaWpsMVdT/CcZwagU5baDnH3c0gnWJflYMp4z6U/KFuOWyMEc8e1b7mNrEUgzb8ff9agA8wMpOcevapJpJFDu67lBwMd6g3ZkVZBtzyc8c0N3C2hXuCVAHUnihvLJ2gemM1NNsWQgrlR91hVNTmTg5HtWUkNaoJVU9gCeuaiGQjlh16Cp2KknbwD1+tRMCQyj8amwrlZG2rkdjj61HMAylgeBUnzRHBXMY61URmEhAXA7c9aE7FLVle6be21V6jire7CggEY6mqrriTIH3j+VPnVsEBsAkHbnpiptuzTRmpBKrxNlue1KZQFG4ZOe9UY5TkADnH5inGQZO/JYd8VV7EqI+5VSrdAzDPWsC4fAZlzkGtSaf7+1S2eKzbheVXGFzlvanJ32LjoVEkkJVVIwMk0E5mITgEdPegttY7MEnpTjyhbG3uBSWpE5CKgyu4/KOMe9NKK7oHkCR55fGcD1xTZCM43cnr9aRo2afy4gWJIVVHXNF7mbLd5b6c3J1TBI7W7dPzrK1u4hljtLe0mM6RQ7DIUK5O4nofrV6fS9U5X+z7jA4ztFY1zZXNlOFvInhYcgPxketTJmMrdzhxKYb4K3+rY4rUVQjAjkeoNV9agMZcbQGU0unymS3LdSvWuSLLNq2O7vg9Qa1LV8cEjYx49qwbdyCvJwe9acTAEAHPpWydtTSDOgtztym4HHAapsD7wAww5HrVC0lCxgnB7e9XQhcI0RAYHkdsVsmrFLuWoFCH5M5I6GrNuAxbrg/pUI+5+8BDD0NJCSJSRkDAzVXsNO5didmLKW27uh9Kt2DOAiSSZcLgtjqazg+d3B3g8Y71ZEpzvORuHI9DT8xvY2vMG0bj1qESMclu/HHpVRJGK/MMZ4yOgNTISc5OGIwMDpVaslKyGT9SpJyTkVQuSduT68mr0oLllH3h61SuAeVPQ98VmwW5WRCzFlGSw/IVLFsCMAACOtRzziKEEA5HUCoi4XbI5I38VNjS7tcsli+B36nFXoYd+0kZH1xVTydpjc9B1rQhbrsBJ6jmhR7g5aaF+IqEw3U9iOlSuwVTsXvgHFVhgNtzyfmz0pUclzuB9eT0rTm0szK19SwreWcEZXHNSIwaL5eA3X6VS84lwei5xTLiUZ4OMDOBRzWKUSe4m2ggABew71kyNI2597H0A7VJLdK5wOR1J9PaqsjqGLYwWHODXPOVzopwcegSSlUAZgD059aSL5vmDEjGDg1TlIKAnJzwKLOXc2NvA/AVgbqHYmFoftRkyeegNTibywynBI96ljkxnHUDoRUvkb2DGPKk9xVRj2Jb/mKwXeN4YKvXJ4poSI8hstVu7hUghV+UjuO1Zkoy+2NG5xyeKLcvQcfe1JxHIEOSAM5z61KtxIEDIdxXtmo8SADbjGOtNUARkqB6kihKwaM1be9KqCQAx6irEN0yvmNsKecdw3tWHHLvcoyn0571P88bqd3yscDHb0raMmZSpo3nukJ+/8j8/Q1HIwkKsrZIPrWRdF2O0H5ejA1YsSkMKqm7aDjn0rZS5nZmTp2V0aDoW5RsIBz9KrKoTGTx/F9KnjcHIVvlPrVSYuysEKkg8ZqpNGaRLIwQhQMljlajckMrYGRVeeRlCs2Nwxk+9QTzylxuwo6NjvWfMhcjJrpw6tg9OtUWcmVTnAB4NE7Fdpz97gn3pjjzIWH8I/WldjirAzF5BtP1pzyf3shvaqkTBXJPQ/0qRQzy7vQ8U73RUktidXw2GXBA496WR2WTjJBOT9fSkBUvvIOFGRn1qC5dncYByR2qXoJasm35DdABxj3rOmkjVzg5weRQ4ZCBuOe9VxGcncQc0+ZhZDhlsEgDvSM3ygKSSTkg+lNGd2SDge9IuWUY6k8+1O5mK8Z81Dxzz9KinTeSYz83I4qV3Kk+g4Bqul00ZVwNpj5Ug4Oad7EMj1O5muYYncyNIihC4yC2OhPvWJqFw6RgPuwBzu6iutvNT129RZraHUIwQAxRMqxH8QGOM+lcH4r1C7uHH22SVrj7uJOGUemKymYNljxlEYnLIue5rl9JmMFw+7O1+ortfFy5nHOBjpmuXubVSqmMAA8g1zR6o1jsi+rBWyOlaVtINqqcc9Ce1Y8PMI56e1XbWTIGOKuLuWtDctWBXb6dff3rUtZCHIIwOmTWNFKcAr9K0rdwcKBz61tFlmyGDhTnlRjNQzOY5D154x602F9ww3XuTU6qsoKv8AdzwfStb3QLQchDoG6EVaifjrkenpVPBSQqwGMdulSo3yAqc85ppj5i5DMHb0/GrSyhYf3nLAnHHasqPYSVUjrmrsTDZnnj5cU4vUHYm5d96HD+lVbhlEjKxOD6etToQgxncDwTVO4G4qxIyCDRLYndkTwlsjHOe9MIHCkDipTKFctzyajd97s2QR3xUPyLTZcSUFSCcggZqzbOVkUA9R1rOjbbtAHB4FWo8bgPzPpSQ7Gm7BmY5z7GmAFXU4DFuMmobdgWw+APf0omuDFklflC53etO63LjG+hLIwLLtXnORUFxKxAByD0yKjS7Eh2uCBjgmmzN+8Kk8dvapburmsYtaFSUbSfmx3+tNRhvBxy3U+lEmGlAz8oGKlCHBAUnjg1jPQ3S6iLGWyX+6OnrVu2hj4CjJ7kjgVHCqjaJM5xwevNalnCyGQOPMwAwjB6n3p04XYpOxBZ25ml+VC7E4JPYfSrvlNAxZ42ABwo54q5p6XIZ7hwqxuu30KgGtIwzGCN4DmEcdQd3ua7IULxujmnV1sY09srWoZnA6fNu759KpXNqTMFKkkLkkHg+4rftrWKaOYCA7s7gXOFOO9LLprN98IVmAIReCMdxRLDuWqJVVJ2OVlhYZUdB61D5RiUFq3b60KyyqVeN1Pyo3ORWNdp8nzMQw7elcs6Ti9TohLmRC4YsSBt4GKbG7AfvWHUiljkdZBnnt0qIoSzgsCOopR2NLdGXo543TDHLkY4706EEFwRxnGaxfLaOUSpnAPT29RWos3YYGOuP51onfcznC2xfTmVdxx2GO9NJELFsZXqPWq/n7165K/d+tRXZe5RUzgDjPc4/pVXVtDJRd9SzMkThW+9k8lj3qvdYIUjqvGMdKbAmxcNwDzz2pbh0A+XOT3o6amMtHZEcyjHznqOMfpVYlg2BkBBn61IWZoRnB/pVVZJCHDZGT370C2GxnoNo3E+nT2qeNxGVUj2NQKWVuMbR1+tOQ4cu/LZ4p2sEpEzyB4XQnB6cVVklKgAHPFEw5baMgc1QnnYQjBG7pzWcpa6hHyJZ50V/mOSo4ANMMpLbiOO2KjVFZN5I3EfnSscE4C4HH1NCfVik1sK8nlKCozk9PekL4Gwcbj81OAxGSR82OPpUIAQD1P6VTJ0sK5LptJwgPBAqt9oW3uoWZBJHG6u6/3sHpU6sNuCcc5GazHkt/tsP2k/6O0q7z/s55pN6GbZZv2F7dS3CeIrcxsxceZI6MoPYqB26celcj4v1GK/1C2Edy1y1rAIZLllK+cwJOQDzgAgZPJxXSeJtSjjvW0zW4oIYJD+4ubdFBtgfuMMfeTpkHnvXL+LrOS2m0aGUxs8diAzRMGVzvb5gR1zUswerNvxgWSeLeSe2RVK0tjJbo38OaveNlb7Rb88d6g06WQRrs+6fUVyLQ3S2GwWpjaT5SV9PSoAPKl61v5cY4GG68Vn6jAY3DYHrwKpMu1iWzY5AOMEVpWzfKSD0rAtpSGGSQetats4xu69wDWqY0bkLjyl46c81cRtyhxnisqCTKFhyO/tWjayfu2U8qR261qmD2Le0y5A47g4pjtsXCgnnmiBjgA/mKmcK+VYfMOjitNCblUbdwljYAnjH9asQSEOwJ+Vv51VMbxnrgA+lAYbznhu3pU3K5uhqIwBOPukdKq3QBQhWwOB9BUUcrImC3PWoUulaXYcg+461XMmtSVvoKSSNjE7h0NSxAFwdvbAI9ar3B2oeM470lpNhmDE5HNR1NU7otk4KMSfpVy3Ybwc81UkyI1PHWore48tmLcHOB9Kp6PUUXc3YmVCrBhtB649KZcxeeAgPyk5NUrS4EjBQPlOTk1dmkKqMenUUaNG8U0ypNEUIBI6YB9hVOR/LcFpCB0AJ61JdTNtZ2O4qQMDt61G9tNPtfjacHI9PSoeux1R01kRTBn+Uce4rStj/okQG5X5B96YLcqpIG7AGcjpmtKxthJIjSZWJSFJ9TTUNRymkhkUASNWAZhJ0J6Z9q1rKIk4l/dg8MQc5FQr/rVDLsCHB56D1+tXUSW3lbaysiKCTjPuD9a3hTtqcsnzKx0F3Gi2Eawh5QFVTtTsPeo4xFaMsEq/Kql1JOAuemaUa4u1GJYfICyMuAfcVmtfC7LMUQxBcFZGx+Irsc1vc44Qm1aS0NGGZJrmdgGhij+VW/hb6VatW827RrxC3ygA9Anv8AjWA9ym0rBuhXH8ZyB7gVVe9cDYlyHdTzIfvY70lNLcv2PMdBrQhuQFScM8PO9RyQT0rmnthcS3EifPG2R06Gob/V2liEaFVVTkleCR6VRXUZTG8JYhPvHA61z1K0JPVHRSoShEr3IRdyRtyOAfTPeqd0zIGwy5QdPepndmmbjCHB3Z9Ko3co89s55ByfSuLodij0JQRMsaoQCxPJ9anc+VbJuHzsflPt0qtZhCVVc7jlif7pqxIrOoTGCoBU+n1rSIno7Cx7hM/BK479j61ZEbJGrE8nJx6jNRxAeSFkIDn+P3qC4mlM6opLIgweaajZamUrstyg4PIU9eOlQM28nJB+tRF2BYsDgdKYsqg7m6d6NGc0h4mAIXIJTggVHcsNw245phVEBcHBPU+9VZJ9xAUFgMmlexk97k5fZHkn8DUfmER7uoqBirxBixzkmqzTARqMkKpJ+oobsrk3Lplyg5X5s/hVGdDI4GRgUi3IlC7Bz2qwgBOTknPNRfmFz2FXEak43HHApsKrGdzDMjDOPSlLYZmI5JwKUglcyHn27U42QhJyEUbR6VUL4U7upp80vmsecKv61Rlk27ixHHY0SY9gu5QIMk/L+tYl/cBYmllb5AMgegq3dSlkYD5VIzzXNnUoZNZsIzj7Itwnmk8gjI6+2az3Zm2MuNPv7u4iaWS0gdwDHBcXCxyEHoQp6Z7ZxSTWRtS9vOjRTpkMrjBX8K3YbAHVrS4nksImt8i9F0QHaQsTIzKeXDD7pGeMYqLxUI0ntidyyRwYZX+8qbiY1b3CEdfaiemxlHVnR+NIVMlu2OcVk6So2yL2HIoornZ0R2NeMBoueop9yivEAwHSiihFvY569UQXIKevQ1agb5gw9aKK0RKNaxYtJtPQ9a1Lfjj06UUVtEbLEbfP0x3q4iBjuyQSO1FFXElkE+WjJBwy8Z9arSKMcdcdTRRQ9xIjLFlGOCO4qtI5JycZz1FFFSyluWRIWjwfpTbcAumQDRRTj0KW5f3fI6Y4HSqFwx3gjqDiiinU6BS+Idp2ST8xwTW0ozEASSBRRVQ2O17mdEcsykfebBNatoOHUdBwAe1FFKmay2JcZdUYkg4z71ejcxpJs788+1FFbozkEcwlhyy/MT1zVHWp5Le3WSJ2UhsAZ6UUVjUfujp/Egtbq4uOZpS7ccnrj0qWaUyN8w46Yooql8CKa99j3uppJFRmygA4+lAw8y7gOuRjiiirTve5NrIr3jiMFVRfmbkkc1Tb7shPJzj04ooqJ7GsNhn3Rt6qR37VVkQM5J7YNFFYS2KRPBGAyntxketae8szscEkAHIooramYyZAVBd1XhOgHpULHymITp0oopkTKkjHLEUnQe+cD2ooqephMqSTHYQAME1QMrBTjjH60UVnIykNnkKpgfQc1ChMifMeo7UUUGXQ0LSFcJ9cVNcHYCFAwKKKuGxK3IYvmO5vXGKjumPmEHOB0FFFJbGi3Kr8OfoTWVeOQoJ5JGSaKKzkEjH1id49LdsksRgc9K5KEcIvY0UVKMjsYtVv7O2hiiuSQigIzorMg9FYjIrB1GWRlZmdmZ23OzHJY+pNFFZNvmHFI//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and telangiectasias are present on the nose, chin, and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and telangiectasias are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24391=[""].join("\n");
var outline_f23_52_24391=null;
var title_f23_52_24392="Sacroiliitis grade 4 example 1";
var content_f23_52_24392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58791%7ERHEUM%2F70511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58791%7ERHEUM%2F70511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 4 example 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral grade 4 sacroiliitis with complete fusion of sacroiliac joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 4 example 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral grade 4 sacroiliitis with fusion of the sacroiliac joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24392=[""].join("\n");
var outline_f23_52_24392=null;
var title_f23_52_24393="Treatment of hypernatremia";
var content_f23_52_24393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypernatremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/52/24393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24393/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/52/24393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24393/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/52/24393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24393/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/52/24393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is most often due to unreplaced water that is lost from the gastrointestinal tract (vomiting or osmotic diarrhea), skin (sweat), or the urine (diabetes insipidus or an osmotic diuresis due to glucosuria in uncontrolled diabetes mellitus or increased urea excretion resulting from catabolism or recovery from renal failure) (",
"    <a class=\"graphic graphic_table graphicRef69879 \" href=\"UTD.htm?27/22/28011\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Hypernatremia due to water loss is called",
"    <strong>",
"     dehydration",
"    </strong>",
"    . This is different from",
"    <strong>",
"     hypovolemia",
"    </strong>",
"    , in which both salt and water are lost [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excessive water loss seldom leads to hypernatremia because the resulting increase in plasma osmolality stimulates thirst (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 1",
"    </a>",
"    ), which leads to increased intake of fluids that lowers the serum sodium into the normal range. Thus, in patients who have access to water, hypernatremia primarily occurs in those who are unable to sense thirst or respond to thirst normally. This is most commonly seen in infants and in adults with impaired mental status, particularly the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/4\">",
"     4",
"    </a>",
"    ]. Elderly patients may also have a diminished thirst response to osmotic stimulation via an unknown mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less commonly, hypernatremia results from the administration of salt in excess of water as can occur with hypertonic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy during a cardiac arrest, inadvertent administration of hypertonic saline during therapeutic abortion, or salt ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Sodium overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will focus on the treatment of hypernatremia induced by water loss, which is the most common cause. The treatment of hypernatremia in patients with impaired thirst, with or without diabetes insipidus, and with primary sodium overload will also be reviewed. The causes and evaluation of patients with hypernatremia and the treatment of central and nephrogenic diabetes insipidus are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to discussing the treatment of patients with hypernatremia, it is helpful to review the determinants of the serum sodium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44164390\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF THE SERUM SODIUM CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the factors that determine the serum sodium concentration is required to appreciate which fluid losses promote the development of hypernatremia and what the composition of intravenous fluids must be to correct the hypernatremia. As an example, how can vomiting or diarrhea, both of which lead to fluid loss that is isosmotic to plasma, induce hypernatremia? In addition, why does the addition of potassium salts (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ) to an intravenous solution of 5 percent dextrose in water diminish the degree to which this solution will lower the serum sodium?",
"   </p>",
"   <p>",
"    In the following discussion, the term effective plasma osmolality (also called plasma tonicity) refers to the osmolal contributions of solutes that are primarily limited to the extracellular or intracellular fluid and are exchangeable (ie, not bound).",
"   </p>",
"   <p>",
"    The extracellular and intracellular fluids are in osmotic equilibrium since water moves freely across most cell membranes. As a result, the effective plasma osmolality is equal to the effective intracellular osmolality and to the effective osmolality of the total body water (TBW). These relationships can be summarized by the following equation:",
"   </p>",
"   <p>",
"    &nbsp;Effective plasma osmolality &nbsp;= &nbsp;(Extracellular solute &nbsp;+ &nbsp;Intracellular solute)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; TBW",
"   </p>",
"   <p>",
"    Exchangeable sodium salts (Nae) are the primary effective extracellular solutes and exchangeable potassium (Ke) and its associated intracellular anions are the primary intracellular solutes; these solutes are the major determinants of the effective plasma osmolality. Glucose, the other major extracellular solute is, in the absence of marked hyperglycemia, present in a much lower molar concentration than sodium (eg, 5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [90",
"    <span class=\"nowrap\">",
"     mg/dL]",
"    </span>",
"    versus 140",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Approximately 30 percent of total body sodium and a smaller fraction of total body potassium are bound in areas such as bone where they are &ldquo;nonexchangeable&rdquo; and therefore not osmotically active. In addition, urea is considered an ineffective osmole, since it freely equilibrates across the cell membranes. When the plasma concentration of an ineffective osmole changes, this change is rapidly reflected within the cells and there is little or no water shift into or out of the cells as there is with changes in the plasma sodium concentration.",
"   </p>",
"   <p>",
"    Thus, the effective plasma osmolality can be expressed as:",
"   </p>",
"   <p>",
"    &nbsp;Effective plasma osmolality &nbsp;&asymp; &nbsp; (2 x Nae &nbsp;+ &nbsp;2 x Ke)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; TBW",
"   </p>",
"   <p>",
"    The multiplier 2 accounts for the osmotic contributions of the anions accompanying sodium and potassium. In the absence of marked hyperglycemia or the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , the above equation can be simplified to:",
"   </p>",
"   <p>",
"    &nbsp;2 x plasma Na &nbsp;&asymp; &nbsp;(2 x Nae &nbsp;+ &nbsp;2 x Ke)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;TBW",
"   </p>",
"   <p>",
"    and then to:",
"   </p>",
"   <p>",
"    &nbsp;Plasma Na &nbsp;&asymp; &nbsp;(Nae &nbsp;+ &nbsp;Ke)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;TBW",
"   </p>",
"   <p>",
"    As shown in the figure, this relationship applies over a wide range of plasma or serum sodium concentrations (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"UTD.htm?42/31/43518\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135016774\">",
"    <span class=\"h2\">",
"     Application to hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is most often due to unreplaced water loss, but can also be induced by the administration of intravenous hypertonic saline or the ingestion of salt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of sodium plus potassium as a determinant of the serum sodium concentration has the following applications to the mechanism and treatment of hypernatremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid loss due to diarrhea is isosmotic to plasma, suggesting no direct effect on the serum sodium concentration. However, the sodium plus potassium concentration in most forms of diarrhea is between 40 and 100",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      with organic solutes, which do not affect the serum sodium, making up the remaining osmoles [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Unreplaced losses of this fluid will tend to raise the serum sodium, since water is lost in excess of sodium and potassium. In contrast, the sodium plus potassium concentration in secretory diarrheas (cholera, VIPoma) is higher and may be similar to that in the plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]; loss of these fluids will have no direct effect on the serum sodium. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H6#H6\">",
"       \"Etiology and evaluation of hypernatremia\", section on 'Gastrointestinal losses'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The sodium plus potassium concentration in vomitus and sweat is similar to that in nonsecretory forms of diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. In one study, for example, the sodium plus potassium concentration in gastric fluid was well below that of the plasma, averaging about 50 to 55",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/10\">",
"       10",
"      </a>",
"      ]. Thus, loss of this fluid will tend to raise the serum sodium even though the fluid is isosmotic to plasma. Hydrochloric acid (HCl) accounts for most of the gap between the osmolality of gastric fluid and the contribution of sodium and potassium. The loss of HCl has no effect on the serum sodium.",
"     </li>",
"     <li>",
"      As described below, treatment of hypernatremia consists of correcting the free water deficit. Dextrose in water, which is isosmotic to plasma but electrolyte free, is most effective. In patients without diabetes mellitus, the glucose will usually be metabolized to carbon dioxide and water or stored as glycogen, none of which contributes to osmolality. Thus, the osmotic effect is similar to the intake of free water.",
"      <br/>",
"      <br/>",
"      However, many patients with hypernatremia have a reduced extracellular fluid volume and some are also potassium depleted (eg, vomiting, diarrhea). The administration of one-quarter or one-half isotonic saline at the same volume will produce a smaller reduction in serum sodium than dextrose in water; the reduction in serum sodium will be even less if potassium is added to the saline solution. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Step three: design a fluid repletion regimen'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, when considering either the etiology or treatment of hypernatremia, it is the",
"    <strong>",
"     sodium plus potassium",
"    </strong>",
"    concentration in the fluid lost or the fluid given,",
"    <strong>",
"     not the osmolality",
"    </strong>",
"    , that determines the effect on the serum sodium. In patients who are both hypernatremic and hypokalemic, the addition of potassium to the administered fluid will diminish the amount of electrolyte-free water that is given, thereby limiting the reduction in serum sodium. (See",
"    <a class=\"local\" href=\"#H21881413\">",
"     'Concurrent electrolyte replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447897394\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of hypernatremia requires both the administration of dilute fluids to correct the water deficit and, when appropriate, interventions to limit further water loss. Many patients also have a concurrent volume deficit due, for example, to gastrointestinal losses. Such patients with hypernatremia will require replacement of",
"    <strong>",
"     both",
"    </strong>",
"    free water and electrolyte deficits.",
"   </p>",
"   <p>",
"    Patients who present with hypernatremia usually have a serious underlying condition that impairs either their ability to respond to thirst or to experience thirst. As a result, such patients usually require hospitalization to correct their hypernatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27431929\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four issues must be addressed when correcting the water deficit in patients with hypernatremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How can the magnitude of the water deficit be estimated? (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Step one: estimate the water deficit'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      At what rate should the hypernatremia be corrected, since lowering the serum sodium concentration too rapidly can lead to neurologic injury? (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Step two: choose a rate of correction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      How does one devise an appropriate fluid repletion regimen? (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Step three: design a fluid repletion regimen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Is there a concurrent volume or potassium deficit that should be simultaneously corrected? (See",
"      <a class=\"local\" href=\"#H21881413\">",
"       'Concurrent electrolyte replacement'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H612535720\">",
"    <span class=\"h2\">",
"     Treatment of specific disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors in addition to correcting the water deficit need to be considered in patients with the following disorders; the supportive data are presented elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes insipidus, in which the serum sodium concentration is usually in the high normal range as long as fluids are available and the patient is able to sense and respond to thirst. The primary aim of therapy in such patients is to decrease the urine output. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"       \"Treatment of central diabetes insipidus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"       \"Treatment of nephrogenic diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothalamic lesions impairing the thirst mechanism with or without diabetes insipidus, in which regular fluid intake throughout the day is required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H9#H9\">",
"       \"Etiology and evaluation of hypernatremia\", section on 'Hypothalamic lesions affecting thirst or osmoreceptor function'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary sodium overload, including salt poisoning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H92923799#H92923799\">",
"       \"Etiology and evaluation of hypernatremia\", section on 'Treatment of salt poisoning'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STEP ONE: ESTIMATE THE WATER DEFICIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The water deficit in the hypernatremic patient can be estimated from the following formula, which is shown below [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Derivation of the water deficit formula'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Serum [Na]",
"    <br/>",
"    &nbsp;Water deficit &nbsp;= &nbsp;Current TBW &nbsp;x &nbsp;(&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; - &nbsp;1)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;140",
"   </p>",
"   <p>",
"    TBW refers to the estimated total body water, which is normally about 60 and 50 percent of",
"    <strong>",
"     lean",
"    </strong>",
"    body weight in younger men and women, respectively, and about 50 and 45 percent of lean body weight in elderly men and women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is probably reasonable to use values about 10 percent lower in hypernatremic patients who are water-depleted.",
"   </p>",
"   <p>",
"    Thus, in a nonobese, middle-aged 60 kg woman with a serum sodium concentration of 168",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    total body water is about 40 percent of body weight and the water deficit can be approximated from:",
"   </p>",
"   <p>",
"    &nbsp;Water deficit &nbsp;= &nbsp;0.4 &nbsp;x &nbsp;60 &nbsp;",
"    <span class=\"nowrap\">",
"     ([168/140]",
"    </span>",
"    &nbsp;- &nbsp;1) &nbsp;= &nbsp;4.8 liters",
"   </p>",
"   <p>",
"    This formula estimates the amount of",
"    <strong>",
"     positive water balance",
"    </strong>",
"    required to return the serum sodium concentration to 140",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Its main use is as a guide to initial therapy, since there are a number of additional factors that must be considered and potential sources of error. These include ongoing water losses (eg, insensible and urinary losses) and a coexisting isosmotic fluid deficit if both sodium and water losses are present (eg, diarrhea, osmotic diuresis with hyperglycemia). These issues are discussed below. (See",
"    <a class=\"local\" href=\"#H136868750\">",
"     'Limitations of the water deficit formulas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20710527\">",
"    <span class=\"h2\">",
"     Alternative approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to estimation of the water deficit is based upon the observation that the administration of 3 mL of electrolyte-free water per kilogram of lean body weight given will lower the serum sodium by approximately 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, in the nonobese 60 kg woman described above, 180 mL (3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    x 60 kg) would be expected to lower the serum sodium by 1",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Since her serum sodium is 28",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    above normal, her estimated water deficit is 5.0 liters (180",
"    <span class=\"nowrap\">",
"     mL/meq",
"    </span>",
"    x 28 meq), which is nearly identical to the 4.8 liter deficit calculated from the water deficit formula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STEP TWO: CHOOSE A RATE OF CORRECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overly rapid correction is potentially dangerous in chronic hypernatremia as it is in chronic hyponatremia, although the risk is not as well defined as it is with hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overly rapid correction of hypernatremia causing neurologic symptoms has been described almost exclusively in children with baseline serum sodium concentrations above 150",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and usually above 155",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    As an example, the mean serum sodium was 163 and 168",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in two series of 9 and 49 infants who developed seizures or cerebral edema following therapy of hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following sequence has been proposed to explain the adverse effect of overly rapid correction of hypernatremia. The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H9#H9\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hypernatremia'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypernatremia initially causes osmotic water movement out of the brain, and the resulting shrinkage of brain cells is thought to be primarily responsible for any initial neurologic symptoms (eg, lethargy, seizures, and coma). Severe manifestations of acute hypernatremia are usually seen at serum sodium concentrations above 158",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"     <li>",
"      Within one to three days, brain volume is largely restored, due both to salt and water movement from the cerebrospinal fluid into the brain (thereby increasing the interstitial volume) and to the uptake of osmotically effective solutes by the brain cells (thereby pulling water back into the cells and restoring the cell volume) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/1,14,17\">",
"       1,14,17",
"      </a>",
"      ]. At this time, neurologic symptoms are less likely and improvement is seen if there were symptoms due to the acute hypernatremia.",
"     </li>",
"     <li>",
"      Rapidly lowering the serum sodium concentration once the cerebral adaptation has occurred causes additional osmotic water movement into brain cells, increasing the brain size above normal. The resulting cerebral edema can lead to an encephalopathy characterized by seizures, permanent neurologic damage, or death [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12509322\">",
"    <span class=\"h2\">",
"     Rate of correction in chronic hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no definitive clinical trials, but data in children (particularly infants) suggest that the maximum safe rate at which the serum sodium concentration should be lowered in patients with chronic hypernatremia is 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/1,15,16,19\">",
"     1,15,16,19",
"    </a>",
"    ]. To be safe, we suggest a",
"    <strong>",
"     maximum rate of correction of the serum sodium of 10",
"     <span class=\"nowrap\">",
"      meq/L",
"     </span>",
"     per day",
"    </strong>",
"    in patients who have had hypernatremia for at least 24 hours. The following findings provide support for this conclusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective case control study included 97 children with hypernatremia and dehydration; the mean baseline serum sodium was 165",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/16\">",
"       16",
"      </a>",
"      ]. The rate of reduction in serum sodium was significantly faster in the children who developed cerebral edema compared with children who had no complications following correction of the hypernatremia (1.0 versus 0.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour).",
"     </li>",
"     <li>",
"      Similar findings were noted in another report in which the rate of reduction in serum sodium was 1.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour in the nine infants who developed seizures compared with 0.6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour or less in 31 infants who did not develop seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/15\">",
"       15",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12509337\">",
"    <span class=\"h2\">",
"     Rate of correction in acute hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the time required for the cerebral adaption, only patients with hypernatremia for at least one day are at risk for overly rapid correction. Any patient who has had hypernatremia for one day or more is considered to have chronic hypernatremia, and should be corrected at the rate noted above. The rare patient with known acute hypernatremia (eg, surgery in a patient with diabetes insipidus if water losses are not replaced or patients with salt poisoning) have not had time for the cerebral adaptation; such patients may develop severe symptoms of hypernatremia but are",
"    <strong>",
"     not",
"    </strong>",
"    likely to be at risk from overly rapid correction. Similar findings have been noted with acute hyponatremia (eg, primary polydipsia, marathon runners). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H9#H9\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hypernatremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H9515951#H9515951\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Duration of hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have acute hypernatremia should be corrected rapidly because the acute increase in serum sodium concentration can lead to irreversible neurologic injury, which may be due in part to osmotic demyelination, similar to the injury caused by a rapid elevation in serum sodium during the treatment of chronic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/20\">",
"     20",
"    </a>",
"    ], and, more rarely, to cerebral hemorrhage. In such patients, we suggest lowering the serum sodium to a near normal level within 24 hours. Either intravenous dextrose in water or hemodialysis can be used. The treatment of acute hypernatremia in patients with diabetes insipidus and salt poisoning is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H92923799#H92923799\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Treatment of salt poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21604058\">",
"    <span class=\"h2\">",
"     Elderly patients with acute clinical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important practical issue is that many patients with hypernatremia are elderly, often residing in long-term care facilities. Hypernatremia in these patients may present clinically as an acute change in mental status. However, the hypernatremia probably occurs gradually in almost all patients. Rare exceptions include elderly patients with known diabetes insipidus, or with known salt poisoning. Barring these exceptions, the serum sodium should be corrected slowly (by no more than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per day) in elderly patients with hypernatremia, even if the clinical history is one of an acute change in mental status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STEP THREE: DESIGN A FLUID REPLETION REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of therapy in patients with hypernatremia begins with estimation of the water deficit, using the formula described above and derived below:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Serum [Na]",
"    <br/>",
"    &nbsp;Water deficit &nbsp;= &nbsp;Current TBW &nbsp;x &nbsp;(&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; - &nbsp;1)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;140",
"   </p>",
"   <p>",
"    TBW refers to the estimated total body water, which is normally about 60 and 50 percent of",
"    <strong>",
"     lean",
"    </strong>",
"    body weight in younger men and women, respectively, and about 50 and 45 percent of lean body weight in elderly men and women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is probably reasonable to use values about 10 percent lower (50 and 40 percent of lean body weight) in hypernatremic patients who are water-depleted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136868750\">",
"    <span class=\"h2\">",
"     Limitations of the water deficit formulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The water deficit formula and the alternative approach described above provide a guide to initial therapy. However, they have a number of potential limitations; as a result, the response to therapy must be carefully monitored. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Step one: estimate the water deficit'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H156542\">",
"     'Monitoring of serum sodium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The limitations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both formulas include estimation of the lean body weight, which may be inaccurate.",
"     </li>",
"     <li>",
"      The formulas estimate the amount of",
"      <strong>",
"       positive water balance",
"      </strong>",
"      that must be attained to lower the serum sodium to a particular goal or at a particular rate. Thus, in addition to replacing the water deficit, ongoing free water losses must also be replaced, including obligatory losses in sweat and stool (about 30 to 40",
"      <span class=\"nowrap\">",
"       mL/h)",
"      </span>",
"      as well as any dilute urinary or gastrointestinal losses. These losses can only be estimated, with the exception of urinary losses in patients with a bladder catheter.",
"      <br/>",
"      <br/>",
"      As described above, &ldquo;dilute&rdquo; in this context refers to a fluid in which the sodium plus potassium concentration is lower than that in the serum. Simply measuring the osmolality of these fluids is likely to be misleading. Both urine and intestinal fluids contain urea and other nonelectrolyte solutes that contribute to the total osmolality but do not contribute to changes in the serum sodium concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/21\">",
"       21",
"      </a>",
"      ]. Similarly, hydrochloric acid lost in gastric fluid and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"       ammonium chloride",
"      </a>",
"      normally lost in urine and stool have no effect on the serum sodium. (See",
"      <a class=\"local\" href=\"#H44164390\">",
"       'Determinants of the serum sodium concentration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link&amp;anchor=H2#H2\">",
"       \"Maintenance and replacement fluid therapy in adults\", section on 'Water balance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The formulas do",
"      <strong>",
"       not include",
"      </strong>",
"      any isosmotic fluid deficit (ie, volume depletion) that often coexists with the water deficit when both sodium and water have been lost, as occurs with diarrhea or an osmotic diuresis. In addition, hypernatremia and, if present, hypokalemia can reduce aldosterone secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/22\">",
"       22",
"      </a>",
"      ]. This may cause mild urinary sodium-wasting, contributing to hypovolemia. (See",
"      <a class=\"local\" href=\"#H21881413\">",
"       'Concurrent electrolyte replacement'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21881403\">",
"    <span class=\"h2\">",
"     Replacing both ongoing water losses and the water deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 60 kg woman with a serum sodium concentration of 168",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    described above had an estimated water deficit of 4.8 L (4800 mL). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Step one: estimate the water deficit'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 28",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    rise in the serum sodium concentration above normal should be corrected at a rate of less than 12",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    to avoid the potentially adverse consequences of overly rapid correction. Thus, the minimum time over which the hypernatremia should be corrected is approximately 2.3 days (28",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    divided by 12",
"    <span class=\"nowrap\">",
"     meq/day).",
"    </span>",
"    To be safe, a reasonable goal is to lower the serum sodium by approximately 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per day. This would require approximately 1700 mL of free water (4800 x",
"    <span class=\"nowrap\">",
"     10/28)",
"    </span>",
"    be given per day, which represents a rate of fluid administration of approximately 70",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    that can be given intravenously as dextrose in water, as water supplementation to tube feedings or, if the patient is able to drink, as oral fluids. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Step two: choose a rate of correction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The water deficit of 4800 mL estimates the positive water balance that must be achieved to lower the serum sodium to 140",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    To achieve this goal, the fluid repletion regimen must also take into account ongoing free water losses. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obligatory water output from sweat and stool, which is approximately 30 to 40",
"      <span class=\"nowrap\">",
"       mL/h.",
"      </span>",
"     </li>",
"     <li>",
"      Ongoing urinary",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal losses that have sodium plus potassium concentrations below the serum sodium concentration. In patients with hypernatremia due to urinary losses, the amount of ongoing losses that must be replaced in addition to the existing water deficit can be calculated using the following equation for the electrolyte-free water clearance, where UV is the urine volume, UNa is the urine sodium concentration, UK is the urine potassium concentration, and SNa is the serum sodium concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/23\">",
"       23",
"      </a>",
"      ]:",
"      <br/>",
"      <br/>",
"      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; UNa &nbsp;+ &nbsp;UK",
"      <br/>",
"      Urine electrolyte free water clearance = UV &nbsp;x &nbsp;(1 &nbsp;- &nbsp;----------------)",
"      <br/>",
"      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SNa",
"      <br/>",
"      <br/>",
"      As an example, the excretion of 100",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      of urine with a sodium plus potassium concentration one-half that of the serum sodium concentration (eg, 84",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the patient whose serum sodium is 168",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      is roughly equivalent to losing 50",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      of electrolyte free water, regardless of the urine osmolality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If this rate of ongoing urinary free water loss was present in the hypernatremic woman discussed above, then the initial rate of free water administration is 160",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    (70 + 40 + 50",
"    <span class=\"nowrap\">",
"     mL/h).",
"    </span>",
"    Serial measurements are required to make certain that the hypernatremia is being corrected at the desired rate. (See",
"    <a class=\"local\" href=\"#H156542\">",
"     'Monitoring of serum sodium'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H265885999\">",
"     'Modifying the rate of water repletion during therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The fluid replacement regimen can also be estimated from the",
"    <strong>",
"     alternative approach",
"    </strong>",
"    to the water deficit formula described above. Assuming that the serum sodium will decrease by 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    if 3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of water is given per hour and that the desired reduction in serum sodium over the first 24 hours is 10",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the initial rate of free water administration should be approximately 75",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour x 60 kg x 10",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    &divide; 24",
"    <span class=\"nowrap\">",
"     h/day).",
"    </span>",
"    To account for 40",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    of obligate water loss in sweat and stool and 50",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    of ongoing urinary free water loss, the total water prescription is 165",
"    <span class=\"nowrap\">",
"     mL/h,",
"    </span>",
"    similar to the 160",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    with the water deficit formula. (See",
"    <a class=\"local\" href=\"#H20710527\">",
"     'Alternative approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5440700\">",
"    <span class=\"h3\">",
"     Risk of hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential complication of the administration of dextrose-containing intravenous fluids at a rapid rate is the development of hyperglycemia. This is more likely to occur in patients who have diabetes mellitus or who are physiologically stressed, leading to the secretion of hormones that can raise the serum glucose (eg, epinephrine and cortisol). Hyperglycemia can lead to an osmotic diuresis, which generates electrolyte-free water losses that will tend to limit the reduction in serum sodium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link&amp;anchor=H17#H17\">",
"     \"Maintenance and replacement fluid therapy in adults\", section on 'Dextrose-induced hyperglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal individuals (ie, no diabetes, not stressed) generally develop hyperglycemia when glucose is infused at rates higher than 3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/24\">",
"     24",
"    </a>",
"    ]. In a patient with a lean body weight of 70 kg, this threshold would be attained by the administration of 5 percent dextrose in water at an infusion rate of 250 to 300 mL per hour. The threshold would be lower in sick patients with high counterregulatory hormone levels and insulin resistance. A 2.5 percent dextrose in water solution, which is not available in many hospitals, can be used in patients who develop hyperglycemia. If this solution is not available, an alternative is to simultaneously infuse 5 percent dextrose in water and one-half isotonic saline in a 1:1 ratio through a single intravenous line using a Y-Site connector, which will create an infusion that is 2.5 percent dextrose in one-quarter isotonic saline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21881413\">",
"    <span class=\"h2\">",
"     Concurrent electrolyte replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with hypernatremia have concurrent extracellular fluid volume depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypokalemia (due, for example, to diarrhea or vomiting). Sodium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potassium can be added to the intravenous fluid as necessary to simultaneously correct the water and electrolyte deficits. However, the addition of sodium or potassium to the replacement fluid decreases the amount of free water that is being given.",
"   </p>",
"   <p>",
"    If, for example, one-quarter isotonic saline (sodium concentration 39",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    is given, then three-quarters of the solution is free water. Thus, to provide 160 mL of free water per hour, which was the estimated requirement in the clinical example above, approximately 210 mL of one-quarter isotonic saline (160 mL times four-thirds) must be given per hour. If 40 meq of potassium is also added because the patient is hypokalemic, then only about one-half of the solution is free water. In this setting, 320 mL must be given per hour to provide 160 mL of free water.",
"   </p>",
"   <p>",
"    An alternative to combining water and sodium (with or without potassium) into one solution is to utilize two intravenous solutions, one for free water and the other for sodium with or without potassium as an isosmotic solution. The major setting in which this might be important is in a patient with severe hypernatremia who also has clinical signs of marked hypovolemia. (See",
"    <a class=\"local\" href=\"#H135016774\">",
"     'Application to hypernatremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156542\">",
"    <span class=\"h2\">",
"     Monitoring of serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limitations of the water deficit formula described in the preceding section, serial measurements of the serum sodium concentration should be performed to assess the efficacy of fluid repletion on the serum sodium concentration. We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have large ongoing water losses, such as those with hyperglycemia and glucosuria or severe nephrogenic diabetes insipidus, the serum sodium should be measured approximately every four hours during the first day of therapy to determine if the fluid repletion regimen is adequate.",
"     </li>",
"     <li>",
"      In patients without such ongoing losses, less frequent monitoring is sufficient. One regimen is to measure the serum sodium at six hours to assess the initial response and, if the serum sodium is falling at the desired rate, every 8 to 12 hours thereafter until the hypernatremia has largely been corrected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Step one: estimate the water deficit'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265885999\">",
"    <span class=\"h2\">",
"     Modifying the rate of water repletion during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the water deficit formulas are based upon an estimate of the total body water and of ongoing fluid losses, neither of which can be measured directly. As a result, the formulas only provide a guide to initial therapy and serial measurements of the serum sodium are essential to determine the response to therapy. (See",
"    <a class=\"local\" href=\"#H136868750\">",
"     'Limitations of the water deficit formulas'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H156542\">",
"     'Monitoring of serum sodium'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rate of fluid administration should be appropriately adjusted if the fall in serum sodium is less than or greater than expected, which can reflect errors in estimated ongoing water losses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the total body water. Suppose, for example, that the goal is to lower the serum sodium by 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first 24 hours (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Step two: choose a rate of correction'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If, with the initial regimen, the serum sodium falls by only 1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the first eight hours of therapy (the desired reduction was approximately 3",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      then the actual positive water balance is 23",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      instead of the desired 70",
"      <span class=\"nowrap\">",
"       mL/h.",
"      </span>",
"      The much smaller than expected response is probably due primarily to ongoing losses that are higher than estimated (eg, 137",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      rather than 90",
"      <span class=\"nowrap\">",
"       mL/h)",
"      </span>",
"      but a higher than estimated total body water could also contribute (see",
"      <a class=\"local\" href=\"#H21881403\">",
"       'Replacing both ongoing water losses and the water deficit'",
"      </a>",
"      above). The fluid repletion regimen should be intensified to account for the higher rate of water loss with continued monitoring of the serum sodium. (See",
"      <a class=\"local\" href=\"#H156332\">",
"       'Monitoring and modification'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If, with the initial regimen, the serum sodium falls by 6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (the desired reduction was approximately 3",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      in the first eight hours of therapy, then ongoing losses were only 45",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      instead of 90",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the total body water is lower than estimated. For the 24-hour reduction in serum sodium to be 10",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      the serum sodium concentration should be lowered no more than 4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      over the next 16 hours. The fluid repletion regimen should be recalculated to achieve this goal with continued monitoring of the serum sodium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178939\">",
"    <span class=\"h1\">",
"     CLINICAL EXAMPLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following case synthesizes the information presented above in an attempt to show how the principles are applied to a particular patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156210\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 70 year-old woman who weighs 60 kg is brought to the emergency department from a long-term care facility with a three to four day history of diarrhea. She has had worsening metal status, and her oral intake has diminished. The evaluation in the emergency department reveals a blood pressure of",
"    <span class=\"nowrap\">",
"     120/50",
"    </span>",
"    mmHg, dry mucous membranes, and a jugular venous pressure below 6 cm H2O. Her serum sodium is 158",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the serum potassium is normal. By this history, she has both a water deficit and an electrolyte (sodium) deficit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156225\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial fluid regimen should include simultaneous repletion of both her water and electrolyte deficits. Although administering isotonic saline through one intravenous line and dextrose in water through a second intravenous line is the simplest approach conceptually, the more common approach is the administration of one-half isotonic saline through a single intravenous line.",
"   </p>",
"   <p>",
"    The following steps should be followed in determining the initial fluid regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Estimate the water deficit",
"      </strong>",
"      &minus; Estimation of the water deficit can be accomplished using the formula shown above, or with the alternative approach. In a hypernatremic woman, the total body water is approximately 40 percent of the lean body weight (it is 50 percent in a hypernatremic man). Thus, the estimated water deficit is 24 x ([158&divide;140] &ndash; 1) or 3.1 L. The alternative approach yields a similar estimated water deficit of 3.2 L. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Step one: estimate the water deficit'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20710527\">",
"       'Alternative approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Decide how quickly to replace the water deficit",
"      </strong>",
"      &minus; Since the patient has been ill for at least three days, it is likely that she has chronic hypernatremia. Thus, her serum sodium should be lowered by no more than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per day. Since her current serum sodium is 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      above normal, the water deficit should be replaced over at least 18 &divide; 10 = 1.8 days, or 43 hours. Thus, to replace the water deficit, the patient should receive 3100 mL &divide; 43 hours = 72 mL of water per hour. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Step two: choose a rate of correction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Add in obligatory water losses",
"      </strong>",
"      &minus; Obligatory water losses from stool and skin are usually about 30 to 40",
"      <span class=\"nowrap\">",
"       mL/hour.",
"      </span>",
"      Thus, water should be given at 72 + 40 = 112",
"      <span class=\"nowrap\">",
"       mL/hour.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H21881403\">",
"       'Replacing both ongoing water losses and the water deficit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Add in other ongoing water losses, if present",
"      </strong>",
"      &minus; Calculating ongoing water losses is necessary in patients who have hypernatremia due to urinary water losses. This can be done by measuring the urine sodium plus potassium concentration and the hourly urine volume. This is described above in more detail. (See",
"      <a class=\"local\" href=\"#H21881403\">",
"       'Replacing both ongoing water losses and the water deficit'",
"      </a>",
"      above.) However, calculating ongoing water losses in stool, as in the current patient, is impractical and not routinely performed.",
"     </li>",
"     <li>",
"      <strong>",
"       Account for electrolyte replacement",
"      </strong>",
"      &minus; If one-half isotonic saline is given, then each liter of intravenous fluid contains only 500 mL of free water. Thus, to provide 112",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      of electrolyte-free water to correct the hypernatremia, 224",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      of one-half isotonic saline should be administered until the hypovolemia is corrected. (See",
"      <a class=\"local\" href=\"#H21881413\">",
"       'Concurrent electrolyte replacement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156332\">",
"    <span class=\"h2\">",
"     Monitoring and modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum sodium should be measured four to six hours after initiating therapy. If the patient has ongoing water losses in her stool or if she has excessive insensible water losses due to fever, the initial fluid regimen of 224",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    of one-half isotonic saline (112",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    of water) will not lower the serum sodium as quickly as expected. Since the regimen was designed to lower the sodium by 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first day, the serum sodium measured at six hours (one fourth of the day) is expected to be 2 to 3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    lower than the presenting serum sodium. (See",
"    <a class=\"local\" href=\"#H156542\">",
"     'Monitoring of serum sodium'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H265885999\">",
"     'Modifying the rate of water repletion during therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Suppose that the patient&rsquo;s serum sodium at six hours is 157",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which is a decrease of 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or only about one-half the expected response. Possible explanations include a higher than estimated total body water",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ongoing water losses. Thus, the rate of free water administration should be increased by 50 to 100 percent with continued monitoring of the serum sodium. (See",
"    <a class=\"local\" href=\"#H265885999\">",
"     'Modifying the rate of water repletion during therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DERIVATION OF THE WATER DEFICIT FORMULA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formula for estimating the free water deficit in a hypernatremic patient can be derived from the following considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24393/abstract/1\">",
"     1",
"    </a>",
"    ]. The quantity of osmoles in the body is equal to the osmolal space [the total body water (TBW)] times the osmolality of the body fluids. The plasma osmolality can be used to represent the osmolality in the TBW since the extracellular osmolality is equal to that in the cells. (See",
"    <a class=\"local\" href=\"#H44164390\">",
"     'Determinants of the serum sodium concentration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, the equation for total body osmoles is:",
"   </p>",
"   <p>",
"    &nbsp;Total body osmoles &nbsp;= &nbsp;TBW &nbsp;x &nbsp;Posm",
"   </p>",
"   <p>",
"    Since the Posm is primarily determined by two times the serum sodium concentration (to account for the accompanying anions)",
"   </p>",
"   <p>",
"    &nbsp;Total body osmoles &nbsp;= &nbsp;TBW &nbsp;x &nbsp;2 &nbsp;x &nbsp;serum [Na]",
"   </p>",
"   <p>",
"    Although sodium is largely limited to the extracellular fluid, the serum sodium concentration can be used in this equation since the extracellular osmolality is equal to that in the cells in which potassium is the primary cation. (See",
"    <a class=\"local\" href=\"#H44164390\">",
"     'Determinants of the serum sodium concentration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If hypernatremia results only from water loss, then:",
"   </p>",
"   <p>",
"    &nbsp;Current total body osmoles &nbsp;= &nbsp;Normal total body osmoles",
"   </p>",
"   <p>",
"    or if the normal serum sodium concentration is 140",
"    <span class=\"nowrap\">",
"     meq/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Current TBW &nbsp;x &nbsp;Serum [Na] &nbsp;= &nbsp;Normal TBW &nbsp;x &nbsp;140",
"   </p>",
"   <p>",
"    The multiple 2 cancels out, since it is present on both sides of the equation. If the equation is solved for normal TBW:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Serum [Na]",
"    <br/>",
"    &nbsp;Normal TBW &nbsp;= &nbsp;Current TBW &nbsp;x &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 140",
"   </p>",
"   <p>",
"    The water deficit can be estimated from:",
"   </p>",
"   <p>",
"    &nbsp;Water deficit &nbsp;= &nbsp;Normal TBW &nbsp;- &nbsp;Current TBW",
"   </p>",
"   <p>",
"    or by substituting from the equation for normal TBW:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Serum [Na]",
"    <br/>",
"    &nbsp;Water deficit &nbsp;= &nbsp;(Current TBW &nbsp;x &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;) &nbsp;- &nbsp;Current TBW",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;140",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Serum [Na]",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; Current TBW &nbsp; x &nbsp; (&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; - &nbsp;1)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 140",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21881446\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypernatremia is most often due to unreplaced water losses that can come from the gastrointestinal tract (vomiting or diarrhea), insensible losses, and sweat losses. Because the associated increase in plasma osmolality stimulates thirst, which leads to the intake of fluids that lowers the serum sodium into the normal range, hypernatremia primarily occurs in patients who are unable to express or respond to thirst normally, such as infants and adults with impaired mental status. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Correction of hypernatremia involves the administration of dilute fluids to correct the water deficit, replacing ongoing water losses, and, when appropriate, limiting further water loss (eg, administrating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      in patients with central diabetes insipidus). Appropriate correction of the serum sodium requires calculation of the water deficit, attention to the rate of correction, estimation of an initial fluid repletion regimen, and determination of whether an extracellular fluid volume deficit also needs to be replaced. (See",
"      <a class=\"local\" href=\"#H447897394\">",
"       'General approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of correction of the hypernatremia depends upon whether the hypernatremia is chronic or acute:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with chronic hypernatremia (ie, hypernatremia that has developed over more than 24 hours), we recommend lowering the serum sodium by less than 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per day (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Overly rapid correction is potentially dangerous in chronic hypernatremia as it is in chronic hyponatremia. A rate of correction of 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per day is considered safe. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Step two: choose a rate of correction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a",
"      <strong>",
"       known",
"      </strong>",
"      abrupt onset of hypernatremia (less than 24 hours duration), as with severe untreated diabetes insipidus in a patient undergoing surgery or with salt poisoning, we recommend that the hypernatremia be corrected rapidly to a near normal level within 24 hours (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Either intravenous dextrose in water or hemodialysis can be used. Rapid correction is warranted because acute hypernatremia can lead to irreversible neurologic injury and there has not been time for the cerebral adaptations that make overly rapid correction hazardous in patient with chronic hypernatremia. (See",
"      <a class=\"local\" href=\"#H12509337\">",
"       'Rate of correction in acute hypernatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even if the history is one of an acute change in mental status, hypernatremia in elderly patients almost always develops gradually, and should be corrected by less than 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initiation of therapy in patients with hypernatremia",
"      <strong>",
"       begins",
"      </strong>",
"      with estimation of the water deficit, using the formula described above. However, in addition to replacing the water deficit, ongoing free water losses must",
"      <strong>",
"       also",
"      </strong>",
"      be replaced, such as insensible losses (about 30 to 40",
"      <span class=\"nowrap\">",
"       mL/h)",
"      </span>",
"      as well as any dilute urinary or gastrointestinal losses. An example of how to make such calculations is presented above. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Step three: design a fluid repletion regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21881403\">",
"       'Replacing both ongoing water losses and the water deficit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calculating the water deficit and ongoing free water losses only provides a guide to initial therapy. To avoid overly rapid correction or under correction in patients with large ongoing water losses, serial measurements of the serum sodium concentration should be performed at four to eight hour intervals for at least the first 12 to 24 hours. (See",
"      <a class=\"local\" href=\"#H156542\">",
"       'Monitoring of serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients presenting with hypernatremia will have chronic hypernatremia. In addition, many of these patients will have a concurrent electrolyte deficit (volume depletion). The following steps should be followed to design an",
"      <strong>",
"       initial",
"      </strong>",
"      treatment strategy in a patient with chronic hypernatremia (see",
"      <a class=\"local\" href=\"#H178939\">",
"       'Clinical example'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Estimate the water deficit. Total body water is approximately 50 percent of lean body weight in hypernatremic men and 40 percent of lean body weight in hypernatremic women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Serum [Na]",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Water deficit &nbsp;= &nbsp;Current TBW &nbsp;x &nbsp;(&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; - &nbsp;1)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;140",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Calculate how quickly to replace the water deficit. In chronic hypernatremia, the total water deficit should be replaced over ([patient&rsquo;s sodium &ndash; 140] &divide; 10) x 24 hours.",
"     </li>",
"     <li>",
"      Divide the estimated water deficit by the number of hours over which to replace the deficit to get the rate of water replacement.",
"     </li>",
"     <li>",
"      Add in obligate water losses from stool and skin, which are usually 40",
"      <span class=\"nowrap\">",
"       mL/hour.",
"      </span>",
"     </li>",
"     <li>",
"      Add in other ongoing water losses from either the gastrointestinal tract or urine, if they can be estimated.",
"     </li>",
"     <li>",
"      Once the desired rate of water administration is calculated, it can be given through a separate intravenous line, or more commonly, with sodium (as half normal saline) in a single intravenous line. If given as half normal saline, the hourly fluid rate must be twice the desired rate of water repletion. As an example, if 100",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      of water is needed, and half normal saline is used, then 200",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      should be administered.",
"     </li>",
"     <li>",
"      Measure the serum sodium six hours after initiating therapy, or four hours after initiating therapy in patients with large ongoing losses such as those with diabetes insipidus or severe hyperglycemia.",
"     </li>",
"     <li>",
"      The repeat sodium, if different than expected, indicates a miscalculation of either the water deficit or the amount of ongoing water loss. Recalculating the water replacement regimen is complex and is discussed above. (See",
"      <a class=\"local\" href=\"#H265885999\">",
"       'Modifying the rate of water repletion during therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.775.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/2\">",
"      Adrogu&eacute; HJ, Madias NE. Hypernatremia. N Engl J Med 2000; 342:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/3\">",
"      Mange K, Matsuura D, Cizman B, et al. Language guiding therapy: the case of dehydration versus volume depletion. Ann Intern Med 1997; 127:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/4\">",
"      Snyder NA, Feigal DW, Arieff AI. Hypernatremia in elderly patients. A heterogeneous, morbid, and iatrogenic entity. Ann Intern Med 1987; 107:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/5\">",
"      Phillips PA, Bretherton M, Johnston CI, Gray L. Reduced osmotic thirst in healthy elderly men. Am J Physiol 1991; 261:R166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/6\">",
"      Phillips PA, Rolls BJ, Ledingham JG, et al. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 1984; 311:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/7\">",
"      EDELMAN IS, LEIBMAN J, O'MEARA MP, BIRKENFELD LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958; 37:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/8\">",
"      Shiau YF, Feldman GM, Resnick MA, Coff PM. Stool electrolyte and osmolality measurements in the evaluation of diarrheal disorders. Ann Intern Med 1985; 102:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/9\">",
"      Castro-Rodr&iacute;guez JA, Salazar-Lindo E, Le&oacute;n-Bar&uacute;a R. Differentiation of osmotic and secretory diarrhoea by stool carbohydrate and osmolar gap measurements. Arch Dis Child 1997; 77:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/10\">",
"      Austin JH, Gammon GD. GASTRIC SECRETION AFTER HISTAMINE: SODIUM AND POTASSIUM CONTENT AND PEPSIN ESTIMATION. J Clin Invest 1931; 10:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/11\">",
"      CONSOLAZIO CF, MATOUSH LO, NELSON RA, et al. Excretion of sodium, potassium, magnesium and iron in human sweat and the relation of each to balance and requirements. J Nutr 1963; 79:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/12\">",
"      Henkin SD, Sehl PL, Meyer F. Sweat rate and electrolyte concentration in swimmers, runners, and nonathletes. Int J Sports Physiol Perform 2010; 5:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/13\">",
"      Sterns RH, Silver SM. Salt and water: read the package insert. QJM 2003; 96:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/14\">",
"      Lien YH, Shapiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest 1990; 85:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/15\">",
"      Kahn A, Brachet E, Blum D. Controlled fall in natremia and risk of seizures in hypertonic dehydration. Intensive Care Med 1979; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/16\">",
"      Fang C, Mao J, Dai Y, et al. Fluid management of hypernatraemic dehydration to prevent cerebral oedema: a retrospective case control study of 97 children in China. J Paediatr Child Health 2010; 46:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/17\">",
"      Pullen RG, DePasquale M, Cserr HF. Bulk flow of cerebrospinal fluid into brain in response to acute hyperosmolality. Am J Physiol 1987; 253:F538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/18\">",
"      Pollock AS, Arieff AI. Abnormalities of cell volume regulation and their functional consequences. Am J Physiol 1980; 239:F195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/19\">",
"      Blum D, Brasseur D, Kahn A, Brachet E. Safe oral rehydration of hypertonic dehydration. J Pediatr Gastroenterol Nutr 1986; 5:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/20\">",
"      Dobato JL, Barriga FJ, Pareja JA, Vela L. [Extrapontine myelinolyses caused by iatrogenic hypernatremia following rupture of a hydatid cyst of the liver with an amnesic syndrome as sequela]. Rev Neurol 2000; 31:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/21\">",
"      Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/22\">",
"      Merrill DC, Skelton MM, Cowley AW Jr. Humoral control of water and electrolyte excretion during water restriction. Kidney Int 1986; 29:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/23\">",
"      Bodonyi-Kovacs G, Lecker SH. Electrolyte-free water clearance: a key to the diagnosis of hypernatremia in resolving acute renal failure. Clin Exp Nephrol 2008; 12:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24393/abstract/24\">",
"      Goodner CJ, Conway MJ, Werbach JH. Control of insulin secretion during fasting hyperglycemia in adult diabetics and in nondiabetic subjects during infusion of glucose. J Clin Invest 1969; 48:1878.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2339 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-89.32.226.102-BE3A184D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24393=[""].join("\n");
var outline_f23_52_24393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21881446\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44164390\">",
"      DETERMINANTS OF THE SERUM SODIUM CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135016774\">",
"      Application to hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H447897394\">",
"      GENERAL APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27431929\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H612535720\">",
"      Treatment of specific disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STEP ONE: ESTIMATE THE WATER DEFICIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20710527\">",
"      Alternative approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STEP TWO: CHOOSE A RATE OF CORRECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12509322\">",
"      Rate of correction in chronic hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12509337\">",
"      Rate of correction in acute hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21604058\">",
"      Elderly patients with acute clinical presentations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STEP THREE: DESIGN A FLUID REPLETION REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H136868750\">",
"      Limitations of the water deficit formulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21881403\">",
"      Replacing both ongoing water losses and the water deficit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5440700\">",
"      - Risk of hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21881413\">",
"      Concurrent electrolyte replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156542\">",
"      Monitoring of serum sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265885999\">",
"      Modifying the rate of water repletion during therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178939\">",
"      CLINICAL EXAMPLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156210\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156225\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156332\">",
"      Monitoring and modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DERIVATION OF THE WATER DEFICIT FORMULA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21881446\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2339|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 1\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/31/43518\" title=\"figure 2\">",
"      Determinants of plasma sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/22/28011\" title=\"table 1\">",
"      Major causes of hypernatremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_52_24394="Interpretation of prostate biopsy";
var content_f23_52_24394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interpretation of prostate biopsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/52/24394/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24394/contributors\">",
"     Ximing J Yang, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/52/24394/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24394/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24394/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24394/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/52/24394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/52/24394/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/52/24394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increasing frequency of prostate cancer over the last decade is due in part to widespread screening with serum prostate specific antigen (PSA) (",
"    <a class=\"graphic graphic_figure graphicRef62493 \" href=\"UTD.htm?43/37/44637\">",
"     figure 1",
"    </a>",
"    ). However, the incidence of the disease was increasing even before the introduction of this test (",
"    <a class=\"graphic graphic_table graphicRef63020 \" href=\"UTD.htm?42/5/43099\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The reasons for this increase are not known; both genetic and environmental factors have been implicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A histologic diagnosis of prostate cancer is generally required prior to instituting therapy for any stage of disease. Needle core biopsy of the prostate under ultrasound (US) guidance is the most common method of obtaining diagnostic tissue. More than one million prostate needle biopsies are performed in the United States each year, and cancer will be diagnosed in approximately 20 to 30 percent of men undergoing prostate needle biopsies in clinical settings.",
"   </p>",
"   <p>",
"    Other potential sources of diagnostic tissue include material from transurethral resections of the prostate (TURP), prostatectomy or cystoprostatectomy specimens, or biopsies from metastatic sites (most often lymph nodes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone).",
"   </p>",
"   <p>",
"    This topic review will provide an overview of biopsy interpretation in prostate cancer. Specific issues related to clinical presentation, diagnosis, staging, and treatment of prostate cancer are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOPSY TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indication for prostate biopsy is an elevation in the serum PSA level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an abnormal digital rectal examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Core needle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, a prostate needle biopsy is performed transrectally with a specially designed 18-gauge needle gun under digital or transrectal ultrasound (TRUS) probe guidance. Accuracy is better with TRUS guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A transperineal approach to the prostate gland that may also permit a successful prostate core biopsy to be performed in men who cannot undergo a transrectal procedure (eg, those with a prior abdominoperineal resection) is rarely used at present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A TRUS-guided prostate biopsy is a relatively simple office technique that requires no sedation or analgesia. However, local anesthesia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    in four quadrants has been shown to be beneficial in alleviating discomfort from the biopsies with increasing numbers of core biopsies. The location of the biopsy is often determined by findings on rectal examination or ultrasound (US). However, these tests are normal in many men, and the diagnosis may be made by systematic prostate biopsies. In the standard TRUS-guided sextant biopsy, a specimen is removed with a biopsy gun from any suspicious areas followed by six tissue cores from the base, midzone, and apical areas of the right and left lobes of the prostate. Each tissue core, typically measuring 0.1 cm in diameter and 1.0 to 1.5 cm in length, is subjected to microscopic examination (",
"    <a class=\"graphic graphic_picture graphicRef57754 \" href=\"UTD.htm?15/4/15439\">",
"     picture 1",
"    </a>",
"    ). Tissue sampling with fewer than six cores or smaller tissue fragments could result in underdetection and an increase in the false negative rate.",
"   </p>",
"   <p>",
"    On the other hand, the sextant biopsy has been largely replaced by extended biopsy schema that sample more areas of the prostate, particularly the lateral aspects. On average, 10 to 12 locations are sampled on a modern prostate core biopsy. When more than six biopsies are taken, some investigators have reported improved prostate cancer detection rates. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14666?source=see_link&amp;anchor=H17#H17\">",
"     \"Prostate biopsy\", section on 'Sampling methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     FNA biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspirate (FNA) biopsy of the prostate with cytologic evaluation was popular in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, in the United States, FNA is not considered sufficiently accurate to be accepted as definitive evidence of prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/10\">",
"     10",
"    </a>",
"    ]. One of the main reasons is that cytologic features of high grade prostatic intraepithelial neoplasia (PIN) may be similar to prostatic adenocarcinoma. Although the architectural features are different, these important diagnostic features cannot be adequately assessed in FNA material, and even experienced pathologists cannot reliably distinguish high grade PIN from prostatic adenocarcinoma based on cytologic features alone.",
"   </p>",
"   <p>",
"    FNA of the prostate gland is particularly unreliable in men who have undergone radiation therapy (RT) or hormonal therapy, because the diagnosis of cancer in posttherapy prostates is primarily based upon architectural features, which are absent in cytologic specimens (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Effect of treatment on biopsy specimens'",
"    </a>",
"    below). One accepted use of FNA cytology is for confirmation of advanced prostate cancer, particularly metastatic disease in a man with a prior history of localized cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HISTOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinoma accounts for more than 95 percent of malignancies of the prostate. Other types of cancers (eg, transitional cell carcinoma, carcinosarcoma, basal cell carcinoma, lymphomas or stromal sarcoma) do occur within the prostate. Here we will focus on the diagnostic features of prostatic adenocarcinoma; more comprehensive discussions of prostate biopsy interpretation are described elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of prostatic adenocarcinoma, particularly on limited material from needle core biopsy, is based upon a constellation of architectural and cytological features [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/11\">",
"     11",
"    </a>",
"    ], and no single feature is sensitive and specific enough to establish diagnosis of prostatic adenocarcinoma in all the cases.",
"   </p>",
"   <p>",
"    Prostatic adenocarcinoma can be diagnosed by the presence of small infiltrating glands with prominent nucleoli. Architecturally, malignant cells form glands that are typically smaller than benign glands (acini or ducts, (",
"    <a class=\"graphic graphic_picture graphicRef76155 \" href=\"UTD.htm?37/42/38565\">",
"     picture 2",
"    </a>",
"    )), and the tumor cells tend to grow in an infiltrative and haphazard manner (",
"    <a class=\"graphic graphic_picture graphicRef66109 \" href=\"UTD.htm?31/48/32516\">",
"     picture 3",
"    </a>",
"    ). In less differentiated tumors, the glandular pattern is irregular, less organized, fused or even absent (",
"    <a class=\"graphic graphic_picture graphicRef63504 \" href=\"UTD.htm?29/23/30069\">",
"     picture 4",
"    </a>",
"    ), and the tumor cells tend to grow in as cords, nests, or sheets, more often in cribriform patterns (",
"    <a class=\"graphic graphic_picture graphicRef52604 \" href=\"UTD.htm?32/41/33429\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cytologically, the cytoplasm of tumor cells is often purple and darker than the pale cytoplasm of the benign epithelium on hematoxylin and eosin (H&amp;E)-stained sections. Tumor cells often display nuclear enlargement, irregularity, and hyperchromasia, and large nucleoli can be seen in the majority of cases (",
"    <a class=\"graphic graphic_picture graphicRef77354 \" href=\"UTD.htm?23/2/23587\">",
"     picture 6",
"    </a>",
"    ). Intraluminal crystalloids, amorphous secretion, or blue-tinged mucin are frequently present in malignant glands, which are uncommonly found in benign glands (",
"    <a class=\"graphic graphic_picture graphicRef52171 \" href=\"UTD.htm?32/4/32836\">",
"     picture 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/11\">",
"     11",
"    </a>",
"    ]. The common morphologic features associated with the diagnosis of malignancy as reported in one series of 250 needle biopsies performed at a single institution are listed in the following table (",
"    <a class=\"graphic graphic_table graphicRef59862 \" href=\"UTD.htm?39/36/40523\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemistry (IHC) using PSA has a limited role in pathologic diagnosis on needle biopsy, because both adenocarcinomas and benign prostatic epithelium are reactive. PSA IHC may be applied in biopsy material to confirm the prostatic origin of epithelial cells, rather than determining whether they are benign or malignant. PSA-positive cells derived from lymph nodes, bone, or from the prostate bed following prostatectomy are more likely to represent malignant cells than are those taken from an intact prostate.",
"   </p>",
"   <p>",
"    IHC for high molecular weight cytokeratin (34bE12) can be performed in selected cases to identify basal cells, which are present in benign prostatic glands, but absent in prostatic adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This immunostain should be used with caution because some cancer cells are positive, and some benign prostatic glands display only weak staining [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another molecule, alpha-methylacyl-CoA racemase (AMACR), also known as P504S, is identified as a molecular marker for prostatic adenocarcinoma by cDNA microarray technology [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. AMACR is a useful marker for tissue diagnosis of prostate cancer in several studies reported by us (",
"    <a class=\"graphic graphic_picture graphicRef77883 \" href=\"UTD.htm?32/52/33606\">",
"     picture 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] and others [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/18,19,23\">",
"     18,19,23",
"    </a>",
"    ]. We recommend a combination of 34bE12 (negative for prostatic adenocarcinoma) and AMACR (positive for prostatic adenocarcinoma) in selected prostate cases when diagnostic uncertainty is encountered.",
"   </p>",
"   <p>",
"    More recently, p63, a nuclear protein present in prostatic basal cells and absent in prostatic adenocarcinomas, has also been shown to be a more reliable marker than 34bE12 because its prominent nuclear staining [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/24\">",
"     24",
"    </a>",
"    ]. We often used an IHC \"cocktail\" which includes AMACR, p63, and 34bE12 antibodies.",
"   </p>",
"   <p>",
"    ERG is a nuclear protein encoded by the",
"    <em>",
"     ERG",
"    </em>",
"    gene (ETS related gene). The fusion between ERG and TMPRSS has been found in prostatic adenocarcinoma. ERG immunostaining has been used to detect the TMPRSS-ERG fusion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/25\">",
"     25",
"    </a>",
"    ]. ERG nuclear staining is detected in approximately 50 percent of prostatic adenocarcinoma cases in this country. The rate of ERG fusion in prostate cancer is even lower for African Americans or Asians compared to Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/26\">",
"     26",
"    </a>",
"    ]. The low sensitivity of ERG immunoreactivity may limit its clinical utility in diagnosis of prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/27\">",
"     27",
"    </a>",
"    ]. However, this fusion gene product is fairly specific for prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/28\">",
"     28",
"    </a>",
"    ]. The clinical value of the ERG fusion in prostate cancer is still under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Small cell (neuroendocrine) carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine cells are normally present in a benign prostatic acinus or duct [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/29\">",
"     29",
"    </a>",
"    ]. Small cell (neuroendocrine) carcinoma, a rare primary tumor of the prostate, is an aggressive and fatal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/30\">",
"     30",
"    </a>",
"    ]. Approximately 50 percent of small cell carcinomas of the prostate coexist with typical adenocarcinomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathologic diagnosis requires the presence of significant number of small undifferentiated (oat cell) carcinoma cells demonstrating neuroendocrine features that are histologically identical to small cell carcinoma of the lung (",
"    <a class=\"graphic graphic_picture graphicRef64298 \" href=\"UTD.htm?15/59/16310\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathology of lung malignancies\", section on 'Small cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small cell neuroendocrine tumors must be differentiated from carcinoid, a well differentiated tumor with neuroendocrine differentiation, which can also be found in the prostate either as primary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/31\">",
"     31",
"    </a>",
"    ] or secondary involvement. The histological diagnosis is not different from that for carcinoid tumors seen in other organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroendocrine differentiation can be confirmed by IHC for neuroendocrine markers such as chromogranin, synaptophysin, or neuron specific enolase. Like small cell cancer involving the lung, small cell carcinoma of the prostate can be positive for thyroid transcription factor-1 (TTF-1); however, the rate of positivity is lower than that of pulmonary small cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because small cell carcinomas of the prostate are typically resistant to hormonal therapy designed for typical prostatic adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/34\">",
"     34",
"    </a>",
"    ], care should be taken to differentiate this entity from adenocarcinoma with focal neuroendocrine differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adenocarcinoma with focal neuroendocrine differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal neuroendocrine differentiation can be observed in several types of prostatic tumors that may have different biologic and biochemical features [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. As an example, focal neuroendocrine differentiation may be seen in 47 to 100 percent of cases of typical prostatic adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/35,36\">",
"     35,36",
"    </a>",
"    ] particularly in high grade tumors. Prostatic adenocarcinoma with neuroendocrine differentiation can be seen in isolated tumor cells as eosinophilic granules.",
"   </p>",
"   <p>",
"    The contribution of focal neuroendocrine differentiation to clinical behavior is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. With currently available information, there is insufficient evidence to support treating these cases differently from typical high grade prostatic adenocarcinoma. We do not routinely perform IHC for neuroendocrine markers to search for focally positive areas of neuroendocrine differentiation in prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urothelial (transitional cell) carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial carcinoma involving the prostate is relatively common. Most of these tumors are due to direct extension into prostatic urethra or prostatic ducts from urothelial carcinoma of urinary bladder, and may be identified in 12 to 48 percent of patients who undergo radical cystectomy for urothelial bladder cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary urothelial carcinoma of the prostate without bladder involvement is rare. Based on the old literature, primary urothelial carcinoma of the prostate was estimated at 1 to 4 percent of prostatic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/40\">",
"     40",
"    </a>",
"    ]. However, these numbers for primary prostatic urothelial carcinoma were obtained before the radical prostatectomy era, and therefore the actual incidence may be lower.",
"   </p>",
"   <p>",
"    Urothelial carcinoma is not infrequent in prostate needle core biopsy, because the needle biopsy samples areas mostly in the prostatic peripheral zone. Because of the differences in clinical management, it is important to recognize urothelial carcinoma, which displays morphologic and immunohistochemical characteristics different from prostatic adenocarcinoma.",
"   </p>",
"   <p>",
"    Distinguishing primary prostatic urothelial carcinoma from the secondary involvement of the prostate by bladder cancer is very difficult on biopsy specimens. Therefore, clinical investigation of the bladder and urinary tract is necessary if urothelial carcinoma is initially detected in the prostate. The presence of prostatic stromal invasion of urothelial carcinoma, which is associated with worse prognosis, should be evaluated in the case of prostatic urothelial carcinoma in addition to the grade and location of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     KEY COMPONENTS OF THE PATHOLOGY REPORT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     When cancer is present",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic diagnosis of prostate cancer on a biopsy specimen must be made without any uncertainty. Any equivocal diagnostic term, such as \"possible\", \"likely\", \"suspicious\", or \"atypical\" should not be accepted as definitive diagnosis of malignancy. Therapy should not be initiated for a patient based on an equivocal or uncertain diagnosis. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Cases with diagnostic uncertainty'",
"    </a>",
"    below.) When prostatic adenocarcinoma is present on needle biopsy, it is not sufficient to simply confirm its presence. The following important features should be included in the pathology report:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gleason score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gleason grading system, which is based solely upon architectural features of prostate cancer cells, closely correlates with clinical behavior. A higher score indicates a greater likelihood of having non-organ confined disease, as well as a worse outcome after treatment of localized disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The Gleason score is the preferred system for grading tumors and has been incorporated as a key prognostic factor in the 2010 TNM staging system for prostate cancer (",
"    <a class=\"graphic graphic_table graphicRef64915 \" href=\"UTD.htm?2/60/3022\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the growth pattern and degree of differentiation, tumors are graded from 1 to 5, with grade 1 being the most, and grade 5 the least differentiated (",
"    <a class=\"graphic graphic_figure graphicRef63496 \" href=\"UTD.htm?10/35/10806\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/43\">",
"     43",
"    </a>",
"    ]. The composite Gleason score is derived by adding together the numerical values for the two most prevalent differentiation patterns (a primary grade and a secondary grade). As an example, if a biopsy consists of predominantly grade three and secondarily grade four disease, the combined score is \"three plus four\" or seven. Gleason scores of two, three, and four are typically considered well-differentiated or low-grade cancers; scores of five, six, or seven represent moderately differentiated cancers; and scores of eight, nine, or ten represent poorly differentiated or high-grade cancers.",
"   </p>",
"   <p>",
"    Gleason score 7 prostate cancer is a heterogeneous entity. In most series, men with Gleason 4 + 3 tumors, where grade 4 is more prevalent than grade 3, have a less favorable outcome than do those with Gleason 3 + 4 disease, where grade 3 is more prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. As an example, multivariate analysis of a single institution series of 1333 men with Gleason 7 prostate cancer found a significantly increased risk of seminal vesicle invasion in those with Gleason 4 + 3 disease (20 versus 9 percent, odds ratio [OR] 2.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/49\">",
"     49",
"    </a>",
"    ]. This observation appears to be more reliable when applied to a prostatectomy specimen rather than one from a biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, a tumor may contain a small component of higher grade tumor in addition to the two predominant patterns; the grade of this minor component is referred to as the tertiary Gleason grade. Traditionally, the tertiary Gleason grade has been noncontributory to the overall Gleason score in biopsy specimens. However, in 2005, the International Society of Urologic Pathology consensus conference recommended that men with biopsy Gleason score 3 + 4 or 4 + 3 prostate cancer and a tertiary pattern 5 should have their cancers classified as Gleason score 8 or 9, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/52\">",
"     52",
"    </a>",
"    ]. These men have a higher pathologic tumor stage and an increased risk of biochemical and clinical recurrence compared to men who have Gleason score 7 disease without a tertiary grade 5 component [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/48,53-56\">",
"     48,53-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The percentage of a tumor consisting of high-grade prostate cancer (ie, combined Gleason pattern 4 or 5) may provide additional prognostic information [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/57\">",
"     57",
"    </a>",
"    ]. In a series of 504 consecutive patients undergoing prostatectomy, an increasing percentage of high-grade tumor was associated with a statistically significant poorer cancer specific survival.",
"   </p>",
"   <p>",
"    The use of the numerical Gleason score is preferable to the three-tiered grading system of low, intermediate, or high grade disease (also known as grade lumping), especially for the initial diagnosis of prostate cancer. The numerical Gleason score is of clinical relevance, since it is a component of most nomograms and tables that estimate prognosis based upon pretreatment variables (",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 5",
"    </a>",
"    ). In contrast, these descriptive terms may be acceptable for men with known, previously treated prostate cancer, or for those with metastatic disease where tumor grading is difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link&amp;anchor=H14#H14\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\", section on 'Predictive tools'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some investigators have proposed \"grade compression\" by lumping prostate cancer into three groups: well differentiated or low grade (Gleason scores of two, three, or four); moderately differentiated or intermediate grade (Gleason scores of five, six, or seven) and poorly differentiated or high grade (Gleason scores of eight, nine, or ten). Grade compression is problematic since Gleason score 6 and 7 tumors are very different in their behaviors. Therefore, for individual patients, the Gleason score is a better indicator than a compressed grade. However, grade compression could be used when a small number of cases are available for study.",
"   </p>",
"   <p>",
"    A diagnosis of prostate cancer with a single digit Gleason grade should be avoided. For example, a diagnosis of \"prostatic adenocarcinoma, Gleason grade 4\" is confusing. It could mean a tumor with Gleason score \"2 + 2\" or four, which is a low grade tumor with limited aggressive behavior, or it could mean a tumor with Gleason score \"4 + 4\" or eight, which is very aggressive. A Gleason score should be reported even for a single small focus of cancer on needle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies suggest that contemporary Gleason grade readings may be significantly higher than they were 10 years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. The effect of this subtle upgrading of Gleason scores over time could be an apparent improvement in outcome for all categories of men with clinically localized prostate cancer (the so-called Will Rogers phenomenon). This issue has the potential to impact on the interpretation of studies that suggest improvements in outcome from treatment over time.",
"   </p>",
"   <p>",
"    There can be substantial interobserver variability in the Gleason grading of a biopsy specimen, particularly for pathologists with less experience interpreting prostate biopsies. In a study in which the interpretations from 29 pathologists were compared with that of an expert in prostate cancer pathology on an average of 278 samples, only 68 percent of samples were correctly classified as Gleason score &lt;7, 7, or &gt;7 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/62\">",
"     62",
"    </a>",
"    ]. Therefore, additional training may be necessary for those pathologists who are unfamiliar with the Gleason grading system.",
"   </p>",
"   <p>",
"    Furthermore, there can be significant discrepancies between the Gleason score, as determined on the prostate biopsy, and the Gleason score based upon the final, pathologic specimen. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link&amp;anchor=H11494930#H11494930\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Side and location of the tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because a partial prostatectomy is not practical, some pathologists do not record which side harbors the tumor. However, documentation of tumor side and location is critical for urologists performing a nerve-sparing radical prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/63\">",
"     63",
"    </a>",
"    ]. Based upon this information, one or both neurovascular bundles may be spared, with a potentially significant impact on postprostatectomy potency rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H683372924#H683372924\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Nerve-sparing approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Estimated tumor volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimate of tumor volume (often generically termed the \"percentage of positive biopsies\") can add clinically significant information to other factors such as the biopsy Gleason score in predicting outcome following therapy for early stage prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link&amp;anchor=H9#H9\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\", section on 'Percentage of positive biopsies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simply stated, tumor involving the majority of five cores sampled on the sextant biopsy represents a more significant disease burden than tumor involving a small portion of one core only. Therefore, both the number of involved cores, and extent of tumor within each core should be included in the pathology report. Tumor involvement within a core can be estimated by measuring either the percentage or the length by centimeter of tumor involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Perineural invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of perineural invasion (PNI) in a prostate biopsy should be reported, since it represents information that may be used by the clinician in planning therapy (",
"    <a class=\"graphic graphic_picture graphicRef69000 \" href=\"UTD.htm?14/4/14403\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. PNI in a core biopsy is an important predictor of pathologic stage, with most [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/64,69,71-75\">",
"     64,69,71-75",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/76\">",
"     76",
"    </a>",
"    ] finding a correlation between PNI on biopsy and extraprostatic extension at the time of prostatectomy. The presence of PNI on pretreatment core biopsy is also associated with a significantly higher likelihood of disease recurrence after radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/75,77\">",
"     75,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finding PNI in a prostatectomy specimen is very common. Although this finding has limited independent predictive value for clinical outcomes, PNI found in a prostatectomy specimen is correlated with a higher volume of prostate cancer in our own experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Extraprostatic extension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although extraprostatic extension is usually documented only at the time of radical prostatectomy, direct extension of tumor cells beyond the confines of the prostatic capsule into periprostatic adipose tissue can occasionally be observed in needle biopsy specimens (",
"    <a class=\"graphic graphic_picture graphicRef80254 \" href=\"UTD.htm?30/42/31397\">",
"     picture 11",
"    </a>",
"    ). As an example, in one series of 150 malignant needle biopsy specimens, invasion of fat was only detected in one case (",
"    <a class=\"graphic graphic_table graphicRef59862 \" href=\"UTD.htm?39/36/40523\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of extraprostatic extension is clinically significant, because it changes the tumor stage to a T3 lesion, which constitutes locally advanced disease (",
"    <a class=\"graphic graphic_table graphicRef64915 \" href=\"UTD.htm?2/60/3022\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of skeletal muscle or ganglions or individual nerves by tumor cells should not be considered to represent extraprostatic extension because these structures can be also observed within the normal prostate gland.",
"   </p>",
"   <p>",
"    Seminal vesicles, and their continuation within the prostate (the ejaculatory duct), can sometimes be seen on needle biopsy specimens. The clinical implication of finding tumor invading the ejaculatory duct on a biopsy specimen is identical to that of a cancer invading the seminal vesicle. The epithelial cells of the seminal vesicles are characterized by the presence of hyperchromatic and pleomorphic nuclei with intracellular golden-brown lipofuscin pigment. A diagnosis of tumor involvement of the seminal vesicles must be made cautiously unless the biopsy is specifically indicated as from the seminal vesicle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/78\">",
"     78",
"    </a>",
"    ]. Although targeted biopsy of the seminal vesicle is not a routine component of tumor staging, it is occasionally performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Presence of a special type of cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, the presence of special types of malignant tumor cells may be observed coexisting with conventional prostatic adenocarcinoma. These components may include but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ductal adenocarcinoma, characterized by the presence of tall columnar tumor cells",
"     </li>",
"     <li>",
"      Small cell carcinoma, characterized by the presence of small cell neuroendocrine components, which should be confirmed using IHC markers",
"     </li>",
"     <li>",
"      A sarcomatoid component along with the carcinoma (carcinosarcoma or sarcomatoid carcinoma), which is characterized by the presence of high-grade spindle tumor cells in addition to typical carcinomatous components",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason to include these tumor components in the diagnostic report is that they are all associated with a poor prognosis, which may require special management [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     When cancer is absent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even if invasive cancer cannot be determined with certainty on the diagnostic prostate biopsy, several benign conditions and features warrant mention in the pathology report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     PIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it does not represent an invasive cancer, the presence of high-grade prostatic intraepithelial neoplasia (PIN) in the needle biopsy specimen is clinically significant and should be included in the report. High-grade PIN is believed to be a precursor to prostatic adenocarcinoma. The presence of high-grade PIN traditionally mandates a follow-up core biopsy to rule out the presence of a coexisting cancer. However, more recent studies have shown that the risk of finding cancer in a patient with isolated high-grade PIN was only slightly higher than that in a patient with a benign prostate biopsy. In contrast, the presence of low-grade PIN is not usually reported, because of its lack of clinical significance and possible confusion with high-grade PIN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26937?source=see_link\">",
"     \"Precancerous lesions of the prostate: Pathology and clinical implications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation, particularly if it is acute, can contribute to an elevated serum PSA; therefore its presence should be specified in the pathology report [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In core biopsy specimens of prostate tissue, a severe inflammatory reaction can mask the diagnostic histologic features of an adenocarcinoma; therefore extreme care should be taken to exclude the presence of a cancer. Nonspecific granulomatous prostatitis, which is characterized by infiltrates of histiocytes and other inflammatory cells along with destruction of the prostate glandular structures, can be misdiagnosed as high-grade prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostatic infarcts are uncommon and in the past have only been reported on TURP material. However, infarcts may be identified in a small number of prostate core needle biopsies (eg, two cases in 2959 biopsies in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/82\">",
"     82",
"    </a>",
"    ]). Histologically, a relatively fresh prostatic infarct is characterized by defined areas of coagulative necrosis with or without hemorrhage, intermediate aged infarcts have reactive stroma and epithelium without necrosis, and older infarcts are characterized by replacement of the stroma by dense fibrosis, and reparative changes (eg, squamous metaplasia at the infarct edges) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/82\">",
"     82",
"    </a>",
"    ]. If an infarct is present in biopsy tissue, it should be included in the diagnosis because it could be responsible for an elevated PSA level, presumably as a result of tissue necrosis releasing massive amounts of PSA into the serum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     BPH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another common condition that might contribute to an elevated serum PSA is benign prostatic hyperplasia (BPH) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/83\">",
"     83",
"    </a>",
"    ]. Some pathologists routinely diagnose BPH in every prostate needle biopsy specimen without sufficient histologic evidence. However, BPH cannot be reliably diagnosed in such specimens because histologic diagnosis requires the presence of hyperplastic nodules, which cannot be assessed on needle core tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/84\">",
"     84",
"    </a>",
"    ]. The \"diagnosis\" of BPH on a needle biopsy specimen should be avoided since it may give a false impression that this is the cause of serum PSA elevation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cases with diagnostic uncertainty",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a prostate biopsy is undertaken, a definite pathologic diagnosis is usually needed for the purpose of clinical management. Unfortunately, definitive diagnosis is not always possible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/85\">",
"     85",
"    </a>",
"    ]. For the diagnosis of invasive cancer to be made, there must be absolutely no doubt on the part of the consulting pathologist. A firm diagnosis of limited prostate cancer on needle core biopsy is one of the most difficult areas in surgical pathology. The histologic features of prostatic adenocarcinoma are complex and may be subtle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/78\">",
"     78",
"    </a>",
"    ]. An error in any step of tissue processing, including tissue fixation, dehydration, embedding, even staining, may interfere with a proper diagnosis.",
"   </p>",
"   <p>",
"    Even if tissue processing is perfect, a definitive diagnosis of cancer may still be difficult for even an experienced pathologist. One of the most common problems that interferes with the ability to make a definitive diagnosis is the size of the suspicious lesion. Most pathologists do not feel comfortable making a diagnosis of malignancy when the focus of concern contains only a few atypical glands or acini.",
"   </p>",
"   <p>",
"    In the situation where the pathologist is suspicious but not totally convinced about a diagnosis of prostate cancer, the term \"atypical glands suspicious for, but not diagnostic of, prostatic adenocarcinoma\" is often applied. Although other pathologists prefer the diagnostic term \"atypical small acinar proliferation suspicious for prostatic adenocarcinoma (ASAP)\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/86\">",
"     86",
"    </a>",
"    ], this phrase has been criticized because it may be confused with a definite cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between 1 and 23 percent of needle biopsy pathology specimens (average 5 percent) have a diagnosis of atypical foci suspicious for carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/89\">",
"     89",
"    </a>",
"    ]. This is not a pathologic entity but a diagnostic term that is used when there is suspicion for but not sufficient evidence to make a definitive diagnosis of cancer. Because the average risk of subsequently documenting cancer following an atypical or suspicious diagnosis is approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/89\">",
"     89",
"    </a>",
"    ], repeat biopsy is necessary within three to six months in all cases. Repeat biopsy should include more sampling of the initial atypical site as well as other areas. Some urologists prefer saturated biopsy methods, in which more than 24 cores are taken.",
"   </p>",
"   <p>",
"    The incidence of an uncertain atypical diagnosis is lower when immunohistochemical staining for high molecular weight cytokeratin (34bE12), p63, or AMACR is applied. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Immunohistochemistry'",
"    </a>",
"    above.) The significance of finding ASAP in men high-grade PIN in a needle biopsy specimen is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26937?source=see_link&amp;anchor=H7#H7\">",
"     \"Precancerous lesions of the prostate: Pathology and clinical implications\", section on 'Clinical significance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the terminology, the following options are available for cases with diagnostic uncertainty:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examine multiple deeper tissue sections. Typically, a total of 10 slides with 30 sections are generated from each prostate tissue core for further evaluation. On deeper levels, a minute suspicious lesion might show sufficient evidence to permit a diagnosis of cancer.",
"     </li>",
"     <li>",
"      Perform IHC for 34bE12 or p63 (negative for prostatic adenocarcinoma) and AMACR (positive for prostatic adenocarcinoma) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunohistochemistry'",
"      </a>",
"      above). However, IHC stains may be false positive or false negative, and the diagnosis of prostatic adenocarcinoma should always be primarily based upon the histological features from H and E-stained slides, rather than IHC stains alone.",
"     </li>",
"     <li>",
"      Rebiopsy of the prostate if clinically indicated. Approximately one-half of men with atypical or suspicious foci will have cancer identified on repeat biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/90-93\">",
"       90-93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Send the slides to a pathologist with greater experience and expertise on prostate lesions for a second opinion to avoid an unnecessary second biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     EFFECT OF TREATMENT ON BIOPSY SPECIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenic influences are important for both the growth and malignant transformation of prostatic tissue. The testes account for 90 to 95 percent of total circulating testosterone, while the adrenal glands produce the remainder. In the prostate, testosterone is converted into dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase (",
"    <a class=\"graphic graphic_figure graphicRef50484 \" href=\"UTD.htm?37/31/38384\">",
"     figure 3",
"    </a>",
"    ). DHT is the primary androgen that stimulates the growth of both benign and malignant prostate tissues.",
"   </p>",
"   <p>",
"    Huggins and Hodges were the first to show that palliation of metastatic disease could be achieved by androgen ablation, which can be accomplished surgically (orchiectomy) or medically by administration of gonadotropin releasing hormone (GnRH) analogs, estrogens, or androgen receptor blockers (anti-androgens) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Although androgen ablation is usually reserved for the treatment of advanced or metastatic prostate cancer, it may be used in men with less advanced disease (ie, clinically organ-confined, or locally advanced) as an adjunct to radiation therapy or surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=see_link\">",
"     \"Initial hormone therapy for metastatic prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Androgen ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the method of androgen ablation, the histologic changes in the prostate gland are indistinguishable. The effects can be shown both in normal secretory epithelium, as well as in adenocarcinoma cells, the vast majority of which maintain the secretory epithelial phenotype (",
"    <a class=\"graphic graphic_table graphicRef50546 \" href=\"UTD.htm?15/12/15563\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Regression and degenerative changes, such as pyknotic nuclei, clear cytoplasm or vacuolated cytoplasm, are evident, while the features of cytologic atypia (eg, nuclear enlargement and prominent nucleoli) that are typically present in adenocarcinoma cells are diminished or absent. These changes can cause difficulty in assessment of prostate biopsies, and may result in underestimation of the extent of disease if hormone therapy was administered prior to a biopsy or prostatectomy. Furthermore, because of the severe histologic changes in tumor cells caused by prior hormonal therapy, the assignment of a Gleason score is unreliable in this situation and is usually withheld.",
"   </p>",
"   <p>",
"    Despite this, the infiltrating pattern of a prostatic adenocarcinoma is mostly retained and can be recognized. In particular, identification of scattered individual malignant epithelial cells in the stroma is diagnostic evidence of prostatic adenocarcinoma (",
"    <a class=\"graphic graphic_picture graphicRef69529 \" href=\"UTD.htm?20/24/20869\">",
"     picture 12",
"    </a>",
"    ). Immunostaining for keratins or for PSA may be helpful in identifying the individual tumor cells in this situation to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other nonspecific histologic changes, including basal cell hyperplasia, transitional cell and squamous cell metaplasia in benign epithelium, and chronic inflammation, may also be present. These nonspecific histologic changes in benign prostatic epithelial cells often provide the pathologist with a clue as to the use of prior hormonal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of estrogen is rarely done; diethylstilbestrol is no longer commercially available. However, estrogens can cause severe squamous metaplasia of benign and malignant prostatic cells in addition to the atrophic changes described above (",
"    <a class=\"graphic graphic_table graphicRef50546 \" href=\"UTD.htm?15/12/15563\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Finasteride and dutasteride",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the potent nonsteroidal anti-androgens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    , 5-alpha reductase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    are considered to be weak anti-androgens. While finasteride blocks the conversion of testosterone to DHT in the prostate gland by inhibiting the type 2 isoenzyme of 5-alpha reductase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/101,102\">",
"     101,102",
"    </a>",
"    ], dutasteride is a dual inhibitor of both the type 1 (present in liver and skin) and type 2 enzymes (in the prostate), and may be more potent than finasteride.",
"   </p>",
"   <p>",
"    In contrast to the steroidal anti-androgens, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    appear to have a limited effect on the histologic appearance of prostatic adenocarcinomas in biopsy specimens (",
"    <a class=\"graphic graphic_table graphicRef50546 \" href=\"UTD.htm?15/12/15563\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/103-107\">",
"     103-107",
"    </a>",
"    ]. Therefore, the histologic diagnosis of prostate cancer on biopsy specimens from men receiving finasteride or dutasteride is not difficult.",
"   </p>",
"   <p>",
"    However, it has been suggested that 5-alpha reductase inhibitors have the potential to alter the Gleason score of prostate cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/108\">",
"     108",
"    </a>",
"    ]. This hypothesis was proposed largely to explain the findings of the Prostate Cancer Prevention trial, a placebo-controlled trial in which men treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    had fewer prostate cancers overall but significantly more tumors of Gleason score 7 to 10 as compared to those in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemoprevention strategies in prostate cancer\", section on '5-Alpha reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The authors cited a similar excess of high Gleason grade prostate cancers in one of the three placebo-controlled trials evaluating 5-alpha reductase inhibitors in men with BPH to support this claim. However, the other two BPH trials did not find more high grade tumors in the treatment arm, and furthermore, all three BPH trials had too few prostate cancers to provide reliable data. Thus, it is not clear that the prostate cancers that developed in the men receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    are truly more aggressive than those that arose in men not receiving finasteride. The relationship between 5-alpha reductase inhibitors and Gleason score remains unsettled. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of either drug may complicate the diagnosis of a prostate cancer because they produce a nearly 50 percent decrease in serum PSA concentrations during the first three months of therapy, which persists as long as the drug is continued [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/101,102,110\">",
"     101,102,110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link&amp;anchor=H10#H10\">",
"     \"Measurement of prostate specific antigen\", section on 'Benign prostatic hyperplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment prostate biopsy is a method of assessing local control after irradiation for prostate cancer. However, it is not commonly performed. Positive results on rebiopsy do not add significant clinical information to that provided by sequential serum PSA measurements following therapy. As a result, rebiopsy is",
"    <strong>",
"     not",
"    </strong>",
"    routine following RT and is only indicated if the PSA is rising and salvage surgery or brachytherapy are being considered. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1656?source=see_link&amp;anchor=H2#H2\">",
"     \"Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of series describing the histologic appearance of the irradiated prostate gland were derived from patients receiving external beam radiation therapy (RT) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Histologic changes following a course of brachytherapy using either radioactive iodine-125 or palladium-103 are qualitatively similar, but may be more pronounced [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link\">",
"     \"Brachytherapy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several weeks after RT has begun, prostatic cells undergo severe degenerative changes, including nuclear shrinkage and cytoplasmic damage. Occasionally, small foci of necrosis will be evident, both in benign and malignant glands. Acute inflammatory cells such as neutrophils, macrophages, and later lymphocytes, accumulate. Gradually, the infiltration of reactive cells subsides and fibrosis develops in areas of tissue damage. This acute phase of reaction to RT is rarely seen in biopsy material because so few patients undergo routine biopsy, and those who do generally have their biopsy at least six months after RT. At that time, residual cancer cells may or may not be evident in the biopsy specimen (see below).",
"   </p>",
"   <p>",
"    In response to RT, benign epithelial and stromal cells develop cytologic atypia, with the epithelial cells having prominent nuclear irregularity, hyperchromasia, and polymorphic changes (",
"    <a class=\"graphic graphic_table graphicRef50546 \" href=\"UTD.htm?15/12/15563\">",
"     table 6",
"    </a>",
"    ). Because of the presence of smudged nuclei, prominent nucleoli are not commonly seen. Irradiated benign epithelial cells often show a slightly spindled appearance termed \"streaming\" histology. Despite marked nuclear atypia, benign glands still retain their lobular pattern (",
"    <a class=\"graphic graphic_picture graphicRef66055 \" href=\"UTD.htm?20/47/21236\">",
"     picture 13",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nonspecific histologic changes such as chronic inflammation, basal cell proliferation, or stromal fibrosis may also be present to varying degrees. Postradiation changes in the benign glands may persist for a long time following prostatic RT, causing difficulty interpreting prostate biopsies in irradiated men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/113\">",
"     113",
"    </a>",
"    ]. In diagnostically difficult cases, immunostaining specific for basal cells may be helpful, often showing positive staining in the benign atypical cells but not in malignant cells.",
"   </p>",
"   <p>",
"    In contrast to the benign glands, the characteristic haphazard infiltrating architectural pattern and cytologic features of malignant prostate glands are often retained (",
"    <a class=\"graphic graphic_table graphicRef50546 \" href=\"UTD.htm?15/12/15563\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/11\">",
"     11",
"    </a>",
"    ]. Irradiated tumor cells may display clear cytoplasm and other degenerative changes or they may show no apparent histological changes from the radiation (",
"    <a class=\"graphic graphic_picture graphicRef64711 \" href=\"UTD.htm?41/21/42326\">",
"     picture 14",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The presence of malignant cells six months following RT to the prostate should not be interpreted as treatment failure. The long doubling time of many prostate tumors, coupled with radiobiologic data indicating that cell death following RT is a postmitotic event, suggests that the time course of disappearance of viable cancer from the prostate is prolonged. As a result, false positive biopsies may be due to delayed tumor regression, and indeterminate biopsies (usually showing radiation effect in viable tumor cells) are of uncertain significance. In one series, for example, 30 percent of indeterminate biopsies showed eventual clearance of tumor at a mean time of 30 months following RT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/114\">",
"     114",
"    </a>",
"    ]. A higher number of indeterminate biopsies may convert to negative in men undergoing brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a biopsy that demonstrates the presence of tumor cells beyond 18 to 24 months is more likely to indicate active disease (either persistence or a local recurrence) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/115-117\">",
"     115-117",
"    </a>",
"    ], however, even this is not absolute. In at least one series, 22 of 46 men who underwent routine prostate biopsy after combined external beam RT and brachytherapy had evidence of residual tumor cells; however, 16 had no evidence of an elevated serum PSA (biochemical failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to the situation in men undergoing prostate biopsies after receiving androgen ablative therapy, it is controversial whether the Gleason grading of recurrent adenocarcinoma following a course of RT is of any significance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/52/24394/abstract/117\">",
"     117",
"    </a>",
"    ] because it may not accurately reflect tumor aggressiveness or clinical behavior. Further studies are necessary to evaluate this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Core needle biopsy of the prostate is used to determine whether or not cancer is present in men with an elevated serum PSA level",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an abnormal digital rectal examination. The standard is to take multiple core biopsies under transrectal ultrasound guidance. Primary diagnosis of prostate cancer by using fine needle aspiration is not acceptable in the United States, although it was widely used in other countries in the past. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical presentation and diagnosis of prostate cancer\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More than 95 percent of malignancies arising in the prostate are adenocarcinoma. The remaining types include urothelial carcinoma, basal cell carcinoma, small cell carcinoma, lymphoma, and sarcomas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Histologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When prostate cancer is present in the biopsy, the combined Gleason score, based upon architectural features of the prostate cancer cells, should be reported because it correlates closely with clinical behavior and has been incorporated into the tumor, node, metastasis (TNM) prognostic group staging system (",
"      <a class=\"graphic graphic_table graphicRef64915 \" href=\"UTD.htm?2/60/3022\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gleason score'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=see_link&amp;anchor=H686719702#H686719702\">",
"       \"Initial staging and evaluation of men with newly diagnosed prostate cancer\", section on 'Staging system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional information that may be derived from the prostate biopsy includes the number of positive cores, the percentage (or length) of cancer in the positive core, the presence of perineural invasion or extraprostatic extension, and the presence of histologic types other than conventional adenocarcinoma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'When cancer is present'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many benign conditions can mimic prostate cancer. The accuracy of pathological diagnosis of prostate cancer can be improved by using immunohistochemistry (IHC) markers; correct interpretation of the IHC results is critical for success. New biomarkers to diagnose prostate cancer and provide prognostic information are promising but require further evaluation before being used in routine clinical practice.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/2\">",
"      Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993; 118:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/3\">",
"      Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/4\">",
"      Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/5\">",
"      Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000; 38:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/6\">",
"      Rifkin MD, Alexander AA, Pisarchick J, Matteucci T. Palpable masses in the prostate: superior accuracy of US-guided biopsy compared with accuracy of digitally guided biopsy. Radiology 1991; 179:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/7\">",
"      Shinohara K, Gulati M, Koppie T, Terris MK. Transperineal prostate biopsy after abdominoperineal resection. J Urol 2003; 169:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/8\">",
"      Andersson L, Hagmar B, Ljung BM, Skoog L. Fine needle aspiration biopsy for diagnosis and follow-up of prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994; 162:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/9\">",
"      Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991; 68:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/10\">",
"      B&ouml;cking A. [Cytopathology of the prostate]. Pathologe 1998; 19:53.",
"     </a>",
"    </li>",
"    <li>",
"     Epstein JI, Yang XJ. Prostate biopsy interpretation, 3rd, Lippincott, Williams, and Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/12\">",
"      Varma M, Lee MW, Tamboli P, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med 2002; 126:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/13\">",
"      Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985; 45:3663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/14\">",
"      Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/15\">",
"      Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/16\">",
"      Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000; 60:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/17\">",
"      Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001; 25:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/18\">",
"      Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/19\">",
"      Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/20\">",
"      Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 2002; 26:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/21\">",
"      Yang XJ, Laven B, Tretiakova M, et al. Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma. Urology 2003; 62:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/22\">",
"      Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002; 26:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/23\">",
"      Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002; 26:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/24\">",
"      Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002; 26:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/25\">",
"      Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011; 35:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/26\">",
"      Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/27\">",
"      He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with \"atypical glands suspicious for cancer\". Am J Surg Pathol 2011; 35:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/28\">",
"      Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/29\">",
"      Azzopardi JG, Evans DJ. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol 1971; 104:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/30\">",
"      T&ecirc;tu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987; 59:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/31\">",
"      Azumi N, Shibuya H, Ishikura M. Primary prostatic carcinoid tumor with intracytoplasmic prostatic acid phosphatase and prostate-specific antigen. Am J Surg Pathol 1984; 8:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/32\">",
"      Mackey JR, Au HJ, Hugh J, Venner P. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998; 159:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/33\">",
"      Ord&oacute;&ntilde;ez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000; 24:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/34\">",
"      Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000; 13:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/35\">",
"      Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/36\">",
"      di Sant'Agnese PA, de Mesy Jensen KL. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987; 18:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/37\">",
"      di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001; 12 Suppl 2:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/38\">",
"      Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/39\">",
"      Casella R, Bubendorf L, Sauter G, et al. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998; 160:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/40\">",
"      Walsh DL, Chang SS. Dilemmas in the treatment of urothelial cancers of the prostate. Urol Oncol 2009; 27:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/41\">",
"      Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/42\">",
"      Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994; 18:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/43\">",
"      Epstein JI. An update of the Gleason grading system. J Urol 2010; 183:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/44\">",
"      Tollefson MK, Leibovich BC, Slezak JM, et al. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 2006; 175:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/45\">",
"      Kang DE, Fitzsimons NJ, Presti JC Jr, et al. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology 2007; 70:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/46\">",
"      Burdick MJ, Reddy CA, Ulchaker J, et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/47\">",
"      Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27:3459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/48\">",
"      Wright JL, Salinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009; 182:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/49\">",
"      Koontz BF, Tsivian M, Mouraviev V, et al. Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. Int J Radiat Oncol Biol Phys 2012; 82:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/50\">",
"      Vira MA, Tomaszewski JE, Hwang WT, et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology 2005; 66:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/51\">",
"      Gonzalgo ML, Bastian PJ, Mangold LA, et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 2006; 67:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/52\">",
"      Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/53\">",
"      Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007; 298:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/54\">",
"      Sim HG, Telesca D, Culp SH, et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 2008; 179:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/55\">",
"      Whittemore DE, Hick EJ, Carter MR, et al. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol 2008; 179:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/56\">",
"      Servoll E, Saeter T, Vlatkovic L, et al. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer. BJU Int 2012; 109:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/57\">",
"      Cheng L, Davidson DD, Lin H, Koch MO. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 2007; 110:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/58\">",
"      Rubin MA, Dunn R, Kambham N, et al. Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy? Am J Surg Pathol 2000; 24:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/59\">",
"      Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/60\">",
"      Mitchell RE, Shah JB, Desai M, et al. Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer. Urology 2007; 70:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/61\">",
"      Jani AB, Johnstone PA, Liauw SL, et al. Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol 2008; 31:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/62\">",
"      Burchardt M, Engers R, M&uuml;ller M, et al. Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays. J Cancer Res Clin Oncol 2008; 134:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/63\">",
"      Sanwick JM, Dalkin BL, Nagle RB. Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical retropubic prostatectomy: application in selecting patients for nerve-sparing surgery. Urology 1998; 52:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/64\">",
"      Sebo TJ, Cheville JC, Riehle DL, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001; 91:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/65\">",
"      Egevad L, Norberg M, Mattson S, et al. Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology 1998; 52:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/66\">",
"      Lewis JS Jr, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 2002; 118:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/67\">",
"      Freedland SJ, Aronson WJ, Csathy GS, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003; 61:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/68\">",
"      Dong F, Jones JS, Stephenson AJ, et al. Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 2008; 179:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/69\">",
"      D'Amico AV, Wu Y, Chen MH, et al. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 2001; 165:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/70\">",
"      Holmes GF, Walsh PC, Pound CR, Epstein JI. Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. Urology 1999; 53:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/71\">",
"      Lee IH, Roberts R, Shah RB, et al. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/72\">",
"      Vargas SO, Jiroutek M, Welch WR, et al. Perineural invasion in prostate needle biopsy specimens. Correlation with extraprostatic extension at resection. Am J Clin Pathol 1999; 111:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/73\">",
"      de la Taille A, Katz A, Bagiella E, et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999; 54:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/74\">",
"      Anderson PR, Hanlon AL, Patchefsky A, et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA &lt;10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 1998; 41:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/75\">",
"      Harnden P, Shelley MD, Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 2007; 109:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/76\">",
"      O'Malley KJ, Pound CR, Walsh PC, et al. Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 2002; 59:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/77\">",
"      Yu HH, Song DY, Tsai YY, et al. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology 2007; 70:111.",
"     </a>",
"    </li>",
"    <li>",
"     Epstein JI. Prostate biopsy interpretation, 2nd, Lippincott-Raven, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/79\">",
"      Neal DE Jr, Clejan S, Sarma D, Moon TD. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992; 20:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/80\">",
"      Okada K, Kojima M, Naya Y, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000; 55:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/81\">",
"      Oppenheimer JR, Kahane H, Epstein JI. Granulomatous prostatitis on needle biopsy. Arch Pathol Lab Med 1997; 121:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/82\">",
"      Milord RA, Kahane H, Epstein JI. Infarct of the prostate gland: experience on needle biopsy specimens. Am J Surg Pathol 2000; 24:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/83\">",
"      Hasui Y, Marutsuka K, Asada Y, et al. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994; 25:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/84\">",
"      Viglione MP, Potter S, Partin AW, et al. Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy? Hum Pathol 2002; 33:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/85\">",
"      Kisner HJ. The gray zone. Clin Lab Manage Rev 1998; 12:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/86\">",
"      Iczkowski KA, Cheng L, Qian J, et al. ASAP is a valid diagnosis. Atypical small acinar proliferation. Hum Pathol 1999; 30:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/87\">",
"      Murphy WM. ASAP is a bad idea. Atypical small acinar proliferation. Hum Pathol 1999; 30:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/88\">",
"      Epstein JI. How should atypical prostate needle biopsies be reported? Controversies regarding the term \"ASAP\". Hum Pathol 1999; 30:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/89\">",
"      Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/90\">",
"      Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol 1997; 21:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/91\">",
"      Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999; 53:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/92\">",
"      Epstein JI. Atypical small acinar proliferation of the prostate gland. Am J Surg Pathol 1998; 22:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/93\">",
"      O'dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000; 55:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/94\">",
"      Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastaic carcinoma of the prostate. Cancer Res 1941; 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/95\">",
"      Huggins C, Stevens RF, Hodges CV. Studies on prostatic carcinoma: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/96\">",
"      T&ecirc;tu B, Srigley JR, Boivin JC, et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 1991; 15:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/97\">",
"      Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994; 18:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/98\">",
"      Vernon SE, Williams WD. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. J Urol 1983; 130:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/99\">",
"      Schenken JR, Burns EL, Kahle PJ. The effect of diethylstibestrol and diethylstibestrol dipropionate on carcinoma of the prostate gland: II. Cytologic changes following treatment. J Urol 1942; 48:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/100\">",
"      FRANKS LM. Estrogen-treated prostatic cancer: the variation in responsiveness of tumor ells. Cancer 1960; 13:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/101\">",
"      Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/102\">",
"      Taskin O, Yalcinoglu AI, Kafkasli A, et al. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease. Fertil Steril 1996; 65:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/103\">",
"      Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/104\">",
"      Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005; 65:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/105\">",
"      Carver BS, Kattan MW, Scardino PT, Eastham JA. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005; 95:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/106\">",
"      Rubin MA, Allory Y, Molini&eacute; V, et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005; 66:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/107\">",
"      Gleave M, Qian J, Andreou C, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study. Prostate 2006; 66:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/108\">",
"      Andriole G, Bostwick D, Civantos F, et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 2005; 174:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/109\">",
"      Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/110\">",
"      Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/111\">",
"      Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982; 6:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/112\">",
"      Gaudin PB, Zelefsky MJ, Leibel SA, et al. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol 1999; 23:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/113\">",
"      Magi-Galluzzi C, Sanderson H, Epstein JI. Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: duration of atypia and relation to type of radiotherapy. Am J Surg Pathol 2003; 27:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/114\">",
"      Crook J, Malone S, Perry G, et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/115\">",
"      Prestidge BR, Hoak DC, Grimm PD, et al. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/116\">",
"      Stock RG, Stone NN, Kao J, et al. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization. Cancer 2000; 89:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/52/24394/abstract/117\">",
"      Goldstein NS, Martinez A, Vicini F, Stromberg J. The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure. Am J Clin Pathol 1998; 110:765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6924 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24394=[""].join("\n");
var outline_f23_52_24394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOPSY TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Core needle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FNA biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HISTOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Small cell (neuroendocrine) carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adenocarcinoma with focal neuroendocrine differentiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urothelial (transitional cell) carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      KEY COMPONENTS OF THE PATHOLOGY REPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      When cancer is present",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gleason score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Side and location of the tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Estimated tumor volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Perineural invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Extraprostatic extension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Presence of a special type of cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      When cancer is absent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - PIN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - BPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cases with diagnostic uncertainty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      EFFECT OF TREATMENT ON BIOPSY SPECIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Androgen ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Estrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Finasteride and dutasteride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6924\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6924|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/37/44637\" title=\"figure 1\">",
"      Prostate cancer by race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/35/10806\" title=\"figure 2\">",
"      Gleason grading prost adenoCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/31/38384\" title=\"figure 3\">",
"      Hypothal pituitary testic axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6924|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/4/15439\" title=\"picture 1\">",
"      Prostatic adenocCA core biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/42/38565\" title=\"picture 2\">",
"      Prostate cancer glands light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/48/32516\" title=\"picture 3\">",
"      Prostate adenocarcinoma light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/23/30069\" title=\"picture 4\">",
"      Prostate adenocarcinoma2 light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/41/33429\" title=\"picture 5\">",
"      Cribriform prost adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/2/23587\" title=\"picture 6\">",
"      Prostate adenocarcinoma3 light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/4/32836\" title=\"picture 7\">",
"      Prostate adenocarcinoma4 light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/52/33606\" title=\"picture 8\">",
"      Prostate adenoCA IHC staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/59/16310\" title=\"picture 9\">",
"      Small cell carcinoma prostate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/4/14403\" title=\"picture 10\">",
"      Prostate CA perineural invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/42/31397\" title=\"picture 11\">",
"      Prost CA extraprost extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/24/20869\" title=\"picture 12\">",
"      Prost adenoCA hormone ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/47/21236\" title=\"picture 13\">",
"      Post radiation atypia benign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/21/42326\" title=\"picture 14\">",
"      Radiation effects prost CA bx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6924|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/5/43099\" title=\"table 1\">",
"      Incidence prostate CA pre PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/36/40523\" title=\"table 2\">",
"      Morphology prost CA needle bx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/60/3022\" title=\"table 3\">",
"      Predict organ confined prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 4\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 5\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/12/15563\" title=\"table 6\">",
"      Post therapy histology prostate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=related_link\">",
"      Brachytherapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=related_link\">",
"      Initial hormone therapy for metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=related_link\">",
"      Initial staging and evaluation of men with newly diagnosed prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26937?source=related_link\">",
"      Precancerous lesions of the prostate: Pathology and clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14666?source=related_link\">",
"      Prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1656?source=related_link\">",
"      Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_52_24395="Differential diagnosis of hallucinogen intoxication";
var content_f23_52_24395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of hallucinogen intoxication",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Toxicologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphetamine/methamphetamine intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic delirium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol or sedative-hypnotic withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroleptic malignant syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synthetic cannabinoids (eg, spice; K2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synthetic cathinones (eg, \"bath salts\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-toxicologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS infection (encephalitis, meningitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head trauma (intracranial hemorrhage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizophrenia (other psychiatric illness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid storm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24395=[""].join("\n");
var outline_f23_52_24395=null;
var title_f23_52_24396="ACC AHA HRS sinus dys";
var content_f23_52_24396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/HRS: Indications for permanent pacing in sinus node dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with sinus node dysfunction in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Documented symptomatic bradycardia, including frequent sinus pauses that produce symptoms. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Symptomatic chronotropic incompetence. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Symptomatic sinus bradycardia that results from required drug therapy for medical conditions. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in patients with sinus node dysfunction in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Heart rate &lt;40 beats per minute when a clear association between significant symptoms consistent with bradycardia and the actual presence of bradycardia has not been documented. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Syncope of unexplained origin when clinically significant abnormalities of sinus node function are discovered or provoked in electrophysiological studies. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The evidence or opinion is less well established that permanent pacing in sinus node dysfunction is beneficial in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Minimally symptomatic patients with chronic heart rate &lt;40 beats per minute while awake. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence that permanent pacing in sinus node dysfunction is not useful and may be harmful in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic patients. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Patients for whom the symptoms suggestive of bradycardia have been clearly documented to occur in the absence of bradycardia. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Symptomatic bradycardia due to nonessential drug therapy. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24396=[""].join("\n");
var outline_f23_52_24396=null;
var title_f23_52_24397="Antimicrobial prophylaxis for gastrointestinal surgery";
var content_f23_52_24397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial prophylaxis for gastrointestinal surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nature of operation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended antimicrobials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dosage before surgery*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal, gastroduodenal",
"       </td>",
"       <td>",
"        Enteric gram-negative bacilli, gram-positive cocci",
"       </td>",
"       <td>",
"        High risk",
"        <sup>",
"         &bull;",
"        </sup>",
"        only: cefazolin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Biliary tract",
"       </td>",
"       <td>",
"        Enteric gram-negative bacilli, enterococci, clostridia",
"       </td>",
"       <td>",
"        High risk",
"        <sup>",
"         &loz;",
"        </sup>",
"        only: cefazolin",
"        <sup>",
"         &Delta;&sect;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Colorectal",
"       </td>",
"       <td rowspan=\"7\">",
"        Enteric gram-negative bacilli, anaerobes, enterococci",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Oral:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neomycin PLUS erythromycin base",
"        <sup>",
"         &yen;",
"        </sup>",
"        or metronidazole",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        &yen;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Parenteral:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cefoxitin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        or cefotetan",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         OR",
"        </strong>",
"        cefazolin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        PLUS metronidazole",
"       </td>",
"       <td class=\"sublist_other\">",
"        500 mg IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         OR",
"        </strong>",
"        ampicillin-sulbactam",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3 g IV",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Appendectomy, non-perforated",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        Same as for colorectal",
"       </td>",
"       <td>",
"        Cefoxitin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        or cefotetan",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 to 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        cefazolin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PLUS metronidazole",
"       </td>",
"       <td>",
"        500 mg IV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug (ampicillin-sulbactam every 2 hours, cefazolin every 4 hours, cefuroxime every 4 hours, cefoxitin every 2 hours, clindamycin every 6 hours, vancomycin every 12 hours) for the duration of the procedure in patients with normal renal function. If vancomycin or a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Morbid obesity, gastrointestinal (GI) obstruction, decreased gastric acidity or GI motility, gastric bleeding, malignancy or perforation, or immunosuppression.",
"     <br/>",
"     &Delta; For patients allergic to penicillins and cephalosporins, clindamycin or vancomycin with either gentamicin, ciprofloxacin, levofloxacin, or aztreonam is a reasonable alternative.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Age &gt;70 years, acute cholecystitis, non-functioning gall bladder, obstructive jaundice, or common bile duct stones.",
"     <br/>",
"     &sect; Cefotetan, cefoxitin, and ampicillin-sulbactam are reasonable alternatives.",
"     <br/>",
"     &yen; In addition to mechanical bowel preparation, 1 g of neomycin plus 1 g of erythromycin at 1 PM, 2 PM, and 11 PM, or 2 g of neomycin plus 2 g of metronidazole at 7 PM and 11 PM the day before an 8 AM operation.",
"     <br/>",
"     &Dagger; Due to increasing resistance of E. coli to fluoroquinolones and ampicillin-sulbactam, local sensitivity profiles should be reviewed prior to use.",
"     <br/>",
"     &dagger; For a ruptured viscus, therapy is often continued for about five days.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, October 2012; Vol. 10 (122):73.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24397=[""].join("\n");
var outline_f23_52_24397=null;
var title_f23_52_24398="AP foot x-ray with metatarsal shaft fracture";
var content_f23_52_24398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AP foot x-ray with metatarsal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The metatarsals 1 through 5 are labeled. There is a fracture in the third metatarsal shaft (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24398=[""].join("\n");
var outline_f23_52_24398=null;
var title_f23_52_24399="Radiograph pulm sporotrich";
var content_f23_52_24399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary sporotrichosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiographs of a 52-year-old man with prior diabetes mellitus, alcoholism, and chronic obstructive pulmonary disease, and pulmonary sporotrichosis. Left panel: PA film shows extensive bilateral upper cavitary lesions. Right panel: Lateral radiograph of the same patient showing extensive upper lobe cavitary infiltration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_52_24399=[""].join("\n");
var outline_f23_52_24399=null;
